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ABSTRACT OF DISSERTATION

THE ROLE OF THE L-TYPE CALCIUM CHANNEL AND ITS CARBOXYLTERMINUS IN THE DEVELOPING AND ADULT HEART
In the heart, the primary role of the L-type calcium channel (LTCC) CaV1.2
is to conduct calcium into cardiomyocytes and initiate contraction. However, part
of the CaV1.2 channel itself, the cleaved carboxyl-terminus (CCt) can also
localize to the nucleus and regulate gene transcription. Therefore, the goal of this
dissertation project was to determine the role and regulation of CCt in the
embryonic and adult heart. The global hypothesis of my dissertation project is
that CCt localizes to the nucleus in embryonic and adult cardiomyocytes via a
calcium-mediated mechanism and regulates transcription. A model of
pharmacological LTCC block-induced perturbation of murine embryonic heart
development was first utilized to study the role of CCt. Pharmacological block at
embryonic day 10 perturbed cardiogenesis and increased CaV1.2 expression.
This result was not mimicked by removal of extracellular calcium or inhibition of
calcium release from the sarcoplasmic reticulum. Co-currently, pharmacological
block decreased CCt nuclear localization in embryonic cardiomyocytes. At the
transcriptional level, CCt suppressed the CaV1.2 promoter. This indicated that the
observed upregulation of CaV1.2 induced by pharmacological block may be
caused by nuclear localization of the transcriptional repressor, CCt. Therefore,
the conclusion was made that pharmacological LTCC block perturbed embryonic
cardiogenesis by decreasing nuclear localization of the transcription factor CCt;
implying a role for CCt in embryonic heart development. Next, CCt regulation
was studied in the adult heart. Similar to the embryonic heart, pharmacological
LTCC block decreased nuclear localization of CCt. Inhibition of the calcium
activated phosphatase calcineurin also decreased CCt nuclear localization. To
determine a role for CCt in the adult heart, CCt nuclear localization was
measured in response to hypertrophic stimuli. Serum-induced cardiomyocyte
hypertrophy significantly increased nuclear localization of CCt. In conclusion, this
dissertation supports the hypothesis that CCt localizes to the nucleus in
embryonic and adult cardiomyocytes, and that this regulation is mediated by
calcium entry into the cardiomyocyte. Furthermore, data from this dissertation
suggests that CCt nuclear localization may play an important role in embryonic
heart development and adult cardiac hypertrophy.

KEYWORDS: L-type Calcium Channel, Calcium Channel Block, Transcription,
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Chapter 1: Background
1.1 The Calcium Channels and their Expression in the Murine Heart
In the murine heart there are two types of voltage-gated calcium channels
present, the L-type calcium channels and the T-type calcium channels. Both Ltype and T-type calcium channels conduct calcium in response to changes in
membrane potential; however, compared to T-type calcium channels, L-type
calcium channels activate at more positive membrane potentials, inactivate more
slowly, and are inactivated by intracellular calcium [1-3].The L-type and T-type
calcium channels each have two subtypes that are expressed in the heart at
varying levels throughout development and into adulthood. The two L-type
calcium channel subtypes are Cav1.2 and Cav1.3 (encoded by the α1C and α1D
gene, respectively), and the two T-type calcium channel subtypes are Cav3.1 and
CaV3.2 (encoded by the α1G and α1H gene, respectively). The exact expression
pattern of calcium channels prior to embryonic day (E) 9.5 of murine heart
development is unclear. However, at E9.5 it is known that in the ventricle, the Ltype calcium channel CaV1.3 is expressed at higher levels than CaV1.2. The only
T-type calcium channel expressed is CaV3.2 [4-6]. By E18, which is close to
parturition, CaV1.2 expression is greater than CaV1.3 expression, CaV3.2
expression has decreased, and CaV3.1 is expressed [7-8]. From neonatal
onward, the L-type calcium channel, CaV1.2, is the predominantly expressed
calcium channel subtype in the atrial and ventricular cardiomyocytes, and is the
major contributor of calcium for excitation-contraction coupling [1, 9-11]. The Ltype calcium channel, CaV1.3, is expressed primarily in the sinoatrial node,
atrioventricular node, and atrial cardiomyocytes [12-13]. The T-type calcium
channel, CaV3.1, is expressed primarily in the sinoatrial node, atrioventricular
node, and the purkinje fibers of the adult murine heart [1-2, 14]. The T-type
calcium channel, CaV3.2, is not known to be present in the adult murine heart [5].
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1.2 The Structure and Regulation of CaV1.2 and its Carboxyl-terminus
The L-type calcium channel, CaV1.2, exists as a heteromultimer (Figure
1.1). The main pore-forming region of CaV1.2 is the α1C subunit (encoded by the
α1C gene). The α1C subunit is composed of four homologous motifs (I-IV)
containing six trans-membrane segments each. The α1C subunit contains the
selectivity filter for calcium, the voltage sensor, and the gating machinery that
controls whether the channel is open or closed [3, 11, 15]. Associated with the
α1C subunit are two auxiliary subunits, a cytosolic β-subunit (CaVβ2) and
covalently-linked α2-δ subunit (reviewed by [11, 16]). The CaVβ2 subunit
regulates channel kinetics and increases current density by increasing trafficking
of α1C to the plasma membrane [3, 17-24]. In contrast to CaVβ2, the α2-δ
subunit has little effect on channel current density, but can affect channel voltage
dependence and kinetics [3, 25-27].
In addition to being regulated by CaVβ2 and the α2-δ auxillary subunits, the
α1C subunit is autoregulated by its carboxyl-terminus, which spans from amino
acids 1507-2171 based on the rabbit sequence [28]. In the heart, the CaV1.2
carboxyl-terminus is post-transcriptionally cleaved, purportedly by calpain,
producing a ~37kDa protein [29-32]. CaV1.2 is cleaved by calpain at a consensus
site that is shared by two other L-type calcium channel family members, CaV1.3
and CaV1.1. In CaV1.2, this site is located between amino acids 1800 and 1801
of the rabbit sequence [33]. However, the same lab mistakenly published a paper
in 2006 stating that CaV1.2 is cleaved at amino acid 1821 [34]. Unfortunately, this
mistake has been perpetuated in the literature by myself and others [29, 35]. It
wasn’t until just a few months ago that the error was recognized. In this
dissertation work I extensively utilize a vector that over-expresses rabbit CaV1.2
from 1821-2171. I will refer to this piece as the cleaved carboxyl-terminus (CCt),
as I mistakenly believed at the time of the experiments that amino acids 18212171 comprised CCt. Please note that CCt actually spans from amino acid 18012171 of CaV1.2.
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The proximal portion of the carboxyl-terminus upstream from the cleavage
site contains the EF-hand [36-37], A [38-39], C [38, 40], and IQ [39-41] motifs
spanning from amino acids 1526-1664 (Figure 1.1). This domain binds
calmodulin, which is involved in calcium-dependent facilitation (CDF) and
calcium-dependent inactivation (CDI) of the CaV1.2 channel [42-44]. The distal
portion of the carboxyl-terminus, CCt, re-associates with and acts as an inhibitor
of CaV1.2 [28, 34]. (Of note, recently published work shows that over-expression
of amino acids 1801-2171 of CaV1.2 has the same functional, inhibitory effect on
CaV1.2 channel as over-expression of amino acids 1821-2171 of CaV1.2 [45].)
However, CCt also contains Serine 1928, which can be phosphorylated by
Protein Kinase A (PKA) or Protein Kinase C (PKC) [46-50]. Calmodulin kinase II
(CaMKII) can also phosphorylate the carboxyl-terminus upstream of the cleavage
site at amino acids 1512 and 1570 [51]. In addition to re-associating with CaV1.2,
CCt is also capable of localizing to the nucleus of neurons and acting as a
transcriptional regulator [35]. In neurons, localization of CCt is regulated by
calcium [35]. Depolarization of neurons, which increases CaV1.2 activity,
decreases nuclear localization of CCt. Application of the pharmacological L-type
calcium channel blocker nimodipine reverses the effect of depolarization, causing
an increase in nuclear localization of CCt. In addition to being regulated by
calcium, levels of nuclear CCt are also regulated developmentally; nuclear CCt
levels in brain tissue increase from E18 to adulthood. Although CaV1.2 is cleaved
in both the brain and in the heart [30, 32], it has not yet been established whether
or not the cleaved portion of CaV1.2 (CCt) can also localize to the nucleus in
cardiomyocytes. Therefore, a central goal of this dissertation will be to determine
if CCt localizes to and has a functional role in the nucleus of cardiomyocytes.
1.3 The Roles of CaV1.2 in the Heart
The primary function of CaV1.2 in the heart is to provide calcium current
(ICa,L) that triggers contraction through a process known as excitation-contraction
coupling [1, 11, 52]. Depolarization of the heart activates the voltage-gated
CaV1.2 channel, allowing calcium to enter (ICa,L). This calcium activates
ryanodine receptors (RYRs) on the sarcoplasmic reticulum (SR), a process
3

known as calcium-induced calcium release. Calcium released from SR increases
global cytosolic calcium concentrations ultimately leading to contraction.
Relaxation occurs by removal of calcium from the cytosol via the sodium/calcium
exchanger (NCX), which pumps calcium into the extracellular space, and the
sarco-endplasmic reticulum calcium ATPase (SERCA) pump, which pumps
calcium back into the SR.
CaV1.2 can also play a very different role in the heart as a regulator of
signaling. The role of CaV1.2 in signaling has primarily been studied in the
context of adult cardiac hypertrophy because an increase in CaV1.2 channel
density is sufficient to induce a hypertrophic response [11, 53-54]. CaV1.2 has
been shown to be involved in regulation of the developmentally expressed gene,
atrial naturetic factor (ANF), and the transcription factor, NFAT, which are both
invovled in pathological hypertrophy [55-56]. Interestingly, signaling pathways
involving CaV1.2 have only been implicated in pathological cardiac hypertrophy,
not physiological hypertrophy [57-60]. This may in part be due to the differences
in how pathological hypertrophy and physiological hypertrophy are stimulated.
Pathological hypertrophy can be caused by, among other things, increased
plasma noradrenaline and increased cardiac sympathetic activity [61-63].
Noradrenaline and sympathetic activity activate the β-adrenergic receptors,
which will ultimately increase ICa,L and calcium signaling. Indeed, pathological
cardiac hypertrophy is characterized by an increase in ANF, which has been
shown to be regulated by CaV1.2 in cardiomyocytes. Pathological hypertrophy al
so exhibits an increase in the expression of fetal genes such as β-Myosin Heavy
Chain (β-MHC) and α-skeletal actin and a decrease in α-MHC and SERCA [6469]. In contrast to pathological hypertrophy, physiological cardiac hypertrophy is
caused by exercise or pregnancy and is reversible [70-72]. Molecularly,
physiological cardiac hypertrophy exhibits an increase in α-MHC [73-74] and β1adrenergic receptor (β1-AR) [74], a decrease in cardiac troponin T type 2
(cTNT)[73] and α-skeletal actin[65], and no change in SERCA[65]. There is
another potential CaV1.2 mediated pathway that could play a role in signaling in
cardiac hypertrophy, CaV1.2 regulating nuclear localization of CCt, Therefore, in
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addition to establishing whether or not CaV1.2 regulates nuclear localization of
CCt in cardiomyoyctes (Section 1.2), this dissertation will also explore CCt
nuclear localization in cardiac hypertrophy.
1.4 Heart Maturation and the Importance of CaV1.2
In addition to playing an important role in contraction and signaling in the
adult heart, CaV1.2 is essential for cardiac development. The process of heart
maturation is complex [75-80]. Mouse cardiac organogenesis begins with the
formation of a linear heart tube that first contracts around embryonic day (E) 8.5
[81]. Between E8.5 and E10, the heart tube folds due to accelerated ventricular
growth and the endocardial cushions (EC) form between the sinus venosus (SV)
and right ventricle (RV). At E10, there is a distinct SV and left ventricle (LV)
divided by the endocardial cushion-filled atrioventricular canal (AVC) [82]. The LV
and RV are separated by the interventricular foramen, externally marked by the
interventricular sulcus (IVC) [82], and the RV continues into the outflow tract
(OFT) (Figure 1.2). Between E10 and E12 the heart continues to fold until the
SV and outflow tract (OFT) are both oriented cranially. At E13.5 the first mature
components of the His-Purkinje system appear [83]. Between E12 and birth, the
SV matures into the right atria and the coronary sinus, the OFT matures into the
aorta and pulmonary artery, and septation occurs between the atria and
ventricles [84]. At E16, the heart is at the fetal stage of maturation [85] and
septation has completed, resulting in distinct left and right atria and ventricles. At
this time the morphological development of the heart is completed, with some
modifications, such as transverse-tubule formation [86], occurring after birth
(E20).
The necessity of functional L-type calcium channels for development has
been exemplified in the literature by three separate mouse models. The first
model is in vitro pharmacological treatment of excised E7.5-E8.5 mouse embryos
[87]. Treatment of excised embryos for two days with the L-type calcium channel
antagonist nifedipine or verapamil induced abnormal development of the right
ventricle without altering cardiac looping. Concurrently, L-type calcium channel
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block altered the expression pattern of GATA4, a transcription factor that plays
an essential role in ventricular development [88-89]. GATA4 mRNA was not
expressed in the ventricles of L-type calcium channel block treated embryos.
This finding suggested that L-type calcium channel block regulates GATA4
expression and that loss of GATA4 may explain the abnormal ventricular
development that was observed. Additionally, L-type calcium channel block
acutely decreased resting and peak intracellular calcium in the hearts of intact
embryos. However, embryos treated for two days with L-type calcium channel
block did not exhibit a significant change in heart rate compared to control.
The second mouse model providing evidence of the necessity of L-type
calcium channels for development is a CaV1.2 knockout mouse model [90].
Knockout of CaV1.2 did not significantly alter embryonic development or heart
rate up to E12.5, but caused embryonic death by E14.5. Whole-cell patch clamp
studies indicated that 81% of cardiomyocyte from CaV1.2 knockout mice
exhibited currents consistent with L-type calcium channel kinetics that were Ltype calcium channel block sensitive. These currents were most likely due to
expression of another L-type calcium channel, CaV1.3. In normal embryonic
development, CaV1.3 is expressed at E9.5 at levels higher than CaV1.2, but by
E18 CaV1.2 levels are higher than CaV1.3 [4-8]. The decrease in CaV1.3 levels
seen in development after E9.5 may explain why the CaV1.2 knockout is unable
to survive past E14.5. In line with this supposition, a follow-up study showed that
CaV1.2 knockout mice displayed a significant increase in CaV1.3 compared to
controls, suggesting that an upregulation in CaV1.3 may allow for embryonic
survival until E14.5.
The third mouse model providing evidence of the necessity of L-type calcium
channels for heart development is a CaVβ2 knockout mouse model [91].
Knockout of CaVβ2 decreased L-type calcium channel current density by
approximately 30% and decreased spontaneous heart rate by approximately
50%. Hearts in CaVβ2 embryos exhibited an abnormal progression of cardiac
looping, narrowing between the right ventricle and outflow tract, and decreased
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myocardial wall thickness. Embryonic lethality was observed after E10.5.
Cardiac-specific disruption of CaVβ2 caused embryonic lethality after E13.5,
which may have been due to incomplete penetrability of the cardiac-specific
promoter driving CaVβ2 disruption. Similar to whole-animal CaVβ2 knockout,
cardiac-specific CaVβ2 disruption decreased spontaneous heart rate and L-type
calcium channel current density. Interestingly, treatment of pregnant mice with
the calcium channel agonist (-)-BayK8644 increased the survival of cardiacspecific CaVβ2 disrupted embryos by one day.
The L-type calcium channel also plays an essential role in heart development
in humans. Timothy Syndrome is caused by a missense mutation in exon 8A of
CaV1.2. This mutation alters channel kinetics, leading to electrophysiological and
morphological heart defects ([92-95], reviewed by [96]).
The above models provide evidence that the L-type calcium channel, CaV1.2
is necessary for embryonic heart development. However, what has yet to be
established is a mechanism for the exact role of CaV1.2 in development. One
possibility is that, similar to the adult heart, calcium entering through CaV1.2
activates signaling pathways that ultimately regulate gene transcription factors. A
second possibility is that CaV1.2 regulates nuclear localization of CCt, which acts
as a transcription factor that regulates genes involved in development. These two
postulates will be explored in this dissertation.
1.5 Overview of the Dissertation Project
The global hypothesis of my dissertation project is that CCt localizes to the
nucleus in embryonic and adult cardiomyocytes via a calcium-mediated
mechanism and regulates transcription. This finding would provide a novel
function for CCt in the heart. Furthermore, it would potentially provide a
mechanism to explain how CaV1.2 directly regulates embryonic heart
development and adult pathological cardiac hypertrophy. This hypothesis will be
tested by the following chapters and specific aims; Figure 1.3 provides a
graphical representation of these aims.
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Chapter 2: Pharmacological L-type Calcium Channel Block Perturbs
Embryonic Cardiogenesis
Specific Aim 1: Establish a model for testing the effects of cardiacspecific pharmacological L-type calcium channel block on embryonic
cardiogenesis.
Rationale: Previous work has shown that pharmacological L-type calcium
channel block, when applied to the entire embryo, can perturb
morphogenesis. However, it is unclear if pharmacological L-type calcium
channel block mediates its effects by directly acting on the heart.
Therefore, the effects of pharmacological L-type calcium channel block will
be tested on excised embryonic hearts to determine if the effects are the
same as those seen in previous whole-embryo studies.
Specific Aim 2: Determine if pharmacological L-type calcium channel
block perturbs cardiogenesis by altering embryonic cardiomyocyte calcium
handling.
Rationale: It is known that in the adult heart CaV1.2 can directly regulate
hypertrophic signaling pathways. However, it has also been shown that in
the adult heart a general increase in intracellular calcium can induce
hypertrophy. This raises the possibility that L-type calcium channel block
perturbs embryonic cardiogenesis by a general alteration of calcium that is
secondary to the L-type calcium channel block. Therefore, the effects of Ltype calcium channel block on calcium handling properties of embryonic
cardiomyocytes will be studied. Additionally, the effects of perturbing
calcium independent of the L-type calcium channel will be studied.
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Chapter 3: CCt Localizes to the Nucleus in Developing Cardiomyocytes and
Regulates CaV1.2 Transcription
Specific Aim 1: Determine if CCt localizes to the nucleus of embryonic
cardiomyocytes.
Rationale: CaV1.2 is cleaved in neurons and in cardiomyocytes. In
neurons this cleaved portion, CCt, has been shown to localize to the
nucleus in neurons. Therefore, it is possible that CCt also localizes to the
nucleus in cardiomyocytes.
Specific Aim 2: Determine if pharmacological L-type calcium channel
block alters nuclear localization of CCt.
Rationale: In neurons it was established that CCt nuclear localization is
regulated by CaV1.2 activity. However, neurons and cardiomyocytes have
very different functions and properties. Specifically, CaV1.2 is involved in
excitation-contraction coupling in cardiomyocytes; therefore CCt nuclear
localization may be differentially regulated in cardiomyocytes.
Specific Aim 3: Determine if CCt can regulate transcription in embryonic
cardiomyocytes.
Rationale: CCt acts as a transcriptional regulator in neurons. Therefore,
the ability of CCt to regulate transcription in cardiomyocytes will also be
determined; this will assist in establishing a physiologically relevant role
for CCt.

Chapter 4: CCt Nuclear Localization is Regulated in the Adult Heart
Specific Aim 1: Confirm that endogenous CCt localizes to the nucleus in
an L-type calcium channel block dependent fashion in the adult heart,
similar to what is seen in embryonic cardiomyocytes.
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Rationale: Embryonic and adult hearts differ in their expression levels of
CaV1.2 as well as their overall structure. Additionally, it has been shown
that CCt nuclear localization levels alter throughout development and into
adulthood. This suggests the possibility that CCt localization could alter
and/or be differentially regulated in the adult heart.
Specific Aim 2: Determine the specific mechanism by which CCt nuclear
localization is regulated.
Rationale: CaV1.2 channel activity regulates CCt nuclear localization.
However, CCt is not known to contain a calcium-binding domain; instead,
the calcium-binding EF hand domain is located upstream in the proximal
carboxyl-terminus. This begs the question of how CaV1.2 signals CCt to
localize to the nucleus. Calmodulin, bound to CaV1.2 and activated by
calcium entry, is capable of activating CaMKII and CaN. It is possible that
this kinase and phosphatase act on CCt to regulate its nuclear
localization. Indeed, phosphorylation and dephosphorylation are well
established regulator of nuclear transport. Additionally, CCt contains
Serine 1928, which is a know site of phosphorylation by PKA and PKC.
Therefore, the role of CaMKII, CaN, PKA, and PKC on CCt nuclear
localization will be explored.
Specific Aim 3: Determine if CCt nuclear localization is altered in cardiac
hypertrophy.
Rationale: Increasing calcium is sufficient to induce pathological cardiac
hypertrophy in vitro. Additionally, CaV1.2 can directly induce hypertrophy
in vitro. Clinical studies have shown that pharmacological L-type calcium
channel block is beneficial in some cases of adult cardiac hypertrophy.
This suggests that CaV1.2, or more specifically CCt, may be playing a role
in pathological cardiac hypertrophy. To begin to test this supposition,
nuclear localization of CCt will be compared in different models of
pathological and physiological hypertrophy.
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Chapter 2: Pharmacological L-type Calcium Channel Block Perturbs
Embryonic Cardiogenesis

2.1 Introduction
Previous work indicates that regulation of calcium is necessary for normal
embryonic heart development. Pharmacological block of the L-type calcium
channel in E7.5-E8.5 excised embryos causes abnormal ventricular development
[87]. Additionally, CaVβ2 knockout mice, which have decreased L-type calcium
channel current density, exhibit morphological cardiac defects [91]. However,
there are drawbacks to these two published models. Both models look at heart
development in the intact embryo. While this is a developmentally relevant
model, it raises the question of whether the perturbations performed in each
model affect the heart directly. For example, treatment of the E7.5-E8.5 embryos
with pharmacological L-type calcium channel block acutely decreased peak
cytosolic calcium in the heart, consistent with L-type calcium channel block.
However, treatment with the same dose of L-type calcium channel block over two
days did not significantly alter heart rate. This suggests that the abnormal
cardiogenesis observed may not have been to due to blocking L-type calcium
channels on the heart, but instead due to block of L-type calcium channels
elsewhere in the embryo. A similar implication could be made with the CaVβ2
knockout mice, since the deletion of CaVβ2 was present throughout the embryo.
Indeed cardiac-specific disruption of CaVβ2, which was examined in the same
paper as the CaVβ2 knockout mouse, was not reported to exhibit perturbed
cardiogenesis [91]. Further evidence that there is an unclear role for L-type
calcium channel in heart development can be seen in CaV1.2 knockout mice.
Knockout of the L-type calcium channel, CaV1.2, leads to embryonic lethality by
E14.5, but there is no reported change in cardiac morphology [90]. However,
there is a compensatory upregulation of the L-type calcium channel, CaV1.3, in
these knockout mice, which may explain the lack of perturbed cardiogenesis [97].
Since there is an unclear role for the L-type calcium channel in normal heart
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development, I wanted to test the hypothesis that specifically blocking the L-type
calcium channel in the heart would perturb embryonic heart development. For
these experiments I chose to use a model of explanted embryonic mouse hearts,
which allows me to look at heart-specific effects of L-type calcium channel block.
This model allows me to address my hypothesis without the perplexities that are
present in the previously published model systems.

2.2 Materials and Methods
2.2.1 Whole-heart Explants and Cell Cultures
All cultures were maintained in Dulbecco’s Minimal Essential Media
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100μg/ml penicillin,
100μg/mL streptomycin, and 2μM L-glutamine. Whole E10 or E16 hearts were
isolated from CD-1 mice (Charles Rivers) and treated for 48 hours with 10μM
nifedipine dissolved in DMSO. Images were taken every 24 hours using a Nikon
Coolpix 5000 camera attached to a Nikon Diaphot 200 microscope with a 10x
lens. For E10 cell cultures, left ventricles were isolated and placed in a nominal
Ca2+-free digestion solution containing 0.5 mg/mL collagenase type II
(Worthington) and 1mg/mL 4x USP pancreatin (Gibco) for 20 minutes. For E16
cell cultures, ventricular tissue was isolated, minced, and immediately placed in
nominal Ca2+-free digestion solution for two 15 minute increments. All cells were
cultured on fibronectin-coated coverslips.
2.2.2 Whole-Cell Calcium Imaging
Calcium imaging was performed as described previously [98-99]. Briefly,
E10 left ventricular cardiomyocytes were cultured for 48 hours with or without
10μM nifedipine. Cardiac myocytes were loaded with 2μM fura-2 for 10 minutes
and de-esterfied in physiological salt solution (PSS) for 10 minutes. All
recordings were performed at 37oC.

Individual cells in a monolayer were

windowed for recording, excited at 340nm and 380nm wavelengths, and the data
was collected with IonOptix (Milton, MA) hardware and analyzed with Clampfit9,
IonOptix, and Origin software. Recordings and measurements were performed
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as follows. Cardiomyocytes were first placed in physiological salts solution (PSS)
that included 1.8mM calcium. This allowed for the measurement of spontaneous
calcium transients. Extracellular calcium was removed by washing in a PSS
solution containing no calcium and 5mM of the calcium chelator EGTA (0
Ca/EGTA). This caused an abrupt cessation of spontaneous transients and
cytosolic calcium levels relaxed to a new steady-state within approximately 8
seconds. Trans-SL diastolic calcium entry was measured by calculating the
difference in calcium levels between the 0 Ca/EGTA level and the mean diastolic
level measured in PSS (labeled ‘i’ in Figure 2.2). Next, SR calcium load was
measured by adding 50mM caffeine for a 25 second interval; the amplitude of the
cytosolic calcium transient (labeled ‘ii’ in Figure 2.2) acts as an index of SR load.
Approximately 20 seconds post caffeine application cytosolic calcium reached a
new steady-state level. The difference between this steady-state calcium level
and the steady-state calcium level achieved upon initial application of 0Ca/EGTA
is an index of SR calcium leak (labeled ‘iii’ in Figure 2.2).
2.2.3 Exon8/8a Splice Variant Assay
Determination of CaV1.2 exon8/8a expression was performed as in [100].
Briefly, E10 whole hearts were treated with or without 10μM nifedipine for 48
hours. cDNA was made from RNA collected using the RNAqueous 4-PCR Kit
(Ambion). Exon 8/8a was amplified using PCR with Platinum Taq DNA
Polymerase (Invitrogen) and the following primers for Cav1.2 Exon 8/8a:
Forward primer 5’-CACCAACTTCGACAACTTCGCC-3
Reverse primer 5’- GCTTTGGCTTTCTCCCTCTCTT-3’
The cycle conditions were as follows: 94oC for 2 min followed by 29 cycles of
94oC for 30sec, 61oC for 30sec, and 72oC for 30sec. The 218bp PCR product
was digested with either BamHI (exon 8) or HaeIII (exon8a) from New England
Biosciences and run out on a 5% TBE gel (Bio-Rad).
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2.3 Results
2.3.1 Pharmacological Block of the L-type Calcium Channel Disrupts
Embryonic Cardiac Morphogenesis
In order to look specifically at effects of L-type calcium channel block on
the heart, whole excised hearts were examined in culture. Hearts excised at
embryonic day 10 (E10) retained gross structural hallmarks during 48 hour
culture; 79% of hearts retained a sulcus at the level of the atrioventricular canal
(AVC) and 74% retained a sulcus at the site of interventricular septation (IVS). In
addition, all E10 hearts retained the ability to spontaneously contract (Figure
2.1). Treatment of excised hearts with 1µM nifedipine for 48 hours resulted in
gross morphological defects; only 12% and 44% of hearts retained a sulcus at
the AVC and IVS, respectively (Figure 2.1B). This effect was dose dependent;
10-100 µM nifedipine decreased the preservation of sulci at the AVC and IVS to
nearly 0%. Nifedipine also affected heart contraction. Nifedipine arrested beating
within seconds of initial application for all doses tested (1-100 µM). However,
after 24 hours of sustained L-type calcium channel block, hearts resumed
spontaneous beating in a dose-dependent fashion (Figure 2.1C). In 1 µM
nifedipine, 100% of hearts resumed spontaneous beating, in 10µM nifedipine
only 88% of hearts resumed beating, and in 100 µM nifedipine all hearts ceased
beating. Similar dose-dependent nifedipine-resistant beating was exhibited
following sustained L-type calcium channel block for 48 hours (Figure 2.1C).
Nifedipine is a dihydropyridine, therefore, as a redundancy test for L-type
calcium channel specificity the phenylalkylamine verapamil was also tested. Both
nifedipine and verapamil are L-type calcium channel blockers, but bind to
different sites of the L-type calcium channel (reviewed by [11]). Similar to
nifedipine, 1µM and 5µM verapamil led to a loss of sulci at the AVC and IVS
(Figure 2.1B). Furthermore, beating initially ceased then resumed in 95% of
hearts after 24 hour treatment with 1µM verapamil and in 40% of hearts treated
with 5µM verapamil (Figure 2.1C).
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The L-type calcium channel plays an essential role in calcium handling in
the heart via its ability to regulate calcium entry. Therefore, the effects of a more
general inhibition of calcium entry were tested by culturing E10 hearts in calciumfree medium. Culturing in calcium-free medium for 48 hours demonstrated a
unique morphology compared to L-type calcium channel block (Figure 2.1B).
These hearts maintained sulci at the AVC and IVS similar to control. In addition,
there was no recovery of contraction as observed at lower doses of L-type
calcium channel block.
2.3.2 Sarcoplasmic Reticulum Calcium Is Altered by Pharmacological Ltype Calcium Channel Block but Does Not Contribute to Cardiac
Morphogenesis
In section 2.3 the observation was made that L-type calcium channel block
and general removal of extracellular calcium had differential effects on heart
morphogenesis as well as the ability of the heart to resume contraction.
Specifically, hearts resumed contraction in the presence of L-type calcium
channel block. In order for contraction to occur, cardiomyocytes must have a
mechanism to allow calcium entry into the cytosol, which can in turn trigger
sarcoplasmic

reticulum

(SR)

calcium

release.

To

determine

how

the

cardiomyocytes may be compensating for reduced L-type calcium channel
function, the effect of L-type calcium channel block on calcium dynamics in the
cardiomyocyte was tested. For these experiments, whole-cell calcium imaging
was used. This technique allows for the measurement of net diastolic transsarcolemmal (trans-SL) calcium entry, sarcoplasmic reticulum (SR) calcium load,
and SR leak into the cytosol [98]. Each of these components contributes to
cytosolic calcium levels.
Whole-cell calcium imaging was performed on cardiomyocytes cultured for
48 hours in the absence of nifedipine (No Drug) or in the presence of 10µM
nifedipine. Consistent with the observed effect of L-type calcium channel block
on whole-heart contraction (Figure 2.1), 4/11 nifedipene treated cardiomyocytes
exhibited spontaneous transients. In the no drug cardiomyocytes, 11/11 exhibited
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spontaneous transients. Treatment of cardiomyocytes with 48 hour nifedipine did
not significantly alter trans-SL diastolic calcium entry compared to no drug control
(Figure 2.3A, black bars). However, 48 hour nifedipine significantly decreased
SR load and SR leak (Figure 2.3B,C; black bars). These changes were not due
to a difference in spontaneous transient frequency. Figure 2.4 shows that there
is no interdependency between spontaneous transient frequency and trans-SL
diastolic calcium entry or SR load.
The observed decrease in SR calcium load and leak raises the possibility
that L-type calcium channel block mediates its effects on morphology via an
alteration in SR calcium handling. In order to test this possibility, excised E10
hearts were treated for 48 hours with micromolar ryanodine, which decreases the
calcium conductance of the ryanodine receptor (RYR) [101]. As expected with a
decrease in calcium release from the SR, treatment with 50µM ryanodine did not
stop spontaneous transients, but did significantly decrease spontaneous
transient frequency (Figure 2.5B). However, 50 µM ryanodine had no observable
effect on cardiac morphology (Figure 2.5A). This finding implies that SR calcium
does not play the same role in cardiac morphogenesis as L-type calcium channel
block.
2.3.3 Pharmacological L-type Calcium Channel Block Induces Nifedipine
Resistance
As described in section 2.4, a subset of 48 hour nifedipine treated
cardiomyocytes exhibited spontaneous transients (48H-ST). In order to
determine how these cardiomyocytes were maintaining their spontaneous
transients, cardiomyocytes were challenged with acute 10µM nifedipine. Acute
treatment with nifedipine, as expected, significantly decreased trans-SL diastolic
calcium entry, SR load, and SR leak in control cardiomyocytes that had no prior
exposure to drug (no drug; Figure 2.3, grey bars). This same effect of acute
nifedipine was also observed in cardiomyocytes treated with 48 hour nifedipine
that

were

quiescent (48H-Q).

Surprisingly,
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48

hour

nifedipine

treated

cardiomyocytes exhibiting spontaneous transients (48H-ST) were not affected by
acute nifedipine challenge (Figure 2.3, grey bars).
One possible explanation for the observed nifedipine resistance is that
these cardiomyocytes contain the nifedipine-resistant exon 8 splice variant of
CaV1.2 [102-103]. This nifedipine-resistant splice variant, termed exon 8a, is
predominant in the vasculature, but is not normally observed in the heart. To
determine if exon 8a was present in the 48 hour nifedipine treated heart,
analytical digest of RT-PCR amplified cDNA was performed (Figure 2.6). Exon 8
contains a restriction site for BamHI while Exon 8a contains a restriction site for
HaeIII. In both control and nifedipine treated hearts, only BamHI cleaved the RTPCR product indicating that only nifedipine-susceptible exon 8 was present. This
suggests that alternative splicing of exon 8 is not involved in the nifedipine
resistance phenomenon.
2.3.4 Pharmacological L-type Calcium Channel Block Induces Nifedipine
Resistance in Fetal Cardiomyocytes without Altering Morphology
The previous experiments show that the L-type calcium channel is
required for normal embryonic development when the heart is undergoing distinct
morphological changes. However at approximately E16 the heart has completed
morphogenesis and septation and instead undergoes proliferative and
hypertrophic growth. This raises the question of the role of the L-type calcium
channel at this distinct stage of development. Therefore the effect of L-type
calcium channel block on E16 hearts was tested in the same manner as the E10
hearts described above. E16 hearts were excised and cultured in the presence or
absence of L-type calcium channel block. Treatment with nifedipine had no
observable effect on heart morphology (Figure 2.7A). The highest dose of
nifedipine (10µM) stopped contraction in approximately 90% of hearts, while the
lowest dose stopped contraction in approximately 50% of hearts (Figure 2.7B).
Because a percentage of E16 hearts contract in the presence of nifedipine,
calcium imaging was performed to determine if nifedipine-treated E16
cardiomyocytes exhibited nifedipine resistance similar to E10 cardiomyocytes.
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Similar to E10 control cardiomyocytes, E16 control cardiomyocytes were
responsive to acute nifedipine treatment. Acute nifedipine decreased transsarcolemmal diastolic calcium entry and significantly decreased SR load and SR
leak. The lack of significance in trans-sarcolemmal diastolic entry was most likely
due to the large standard error. Sample size would need to be increased in order
to resolve this issue. All 48 hour 10 µM nifedipine treated cardiomyocytes
measured exhibited spontaneous transients despite the small percentage of
contracting hearts observed with the treatment of 10µM nifedipine for 48 hours.
Similar to 48 hour treated E10 cardiomyocytes, 48 hour treated E16
cardiomyocytes showed no significant change in trans-sarcolemmal diastolic
calcium entry compared to control. However, unlike the E10 cardiomyocytes, 48
hour treated E16 cardiomyocytes showed no significant change in SR calcium
load or SR calcium leak compared to control (Figure 2.8). Treatment with acute
nifedipine did not significantly alter trans-SL diastolic calcium levels, SR load, or
SR leak. These findings are similar to the subset of nifedipine-resistant E10
cardiomyocytes that exhibited spontaneous transients (Figure 2.3).

2.4 Discussion
The primary finding of this chapter is that pharmacological blockade of the
L-type calcium channel perturbs development of the embryonic heart; this effect
is not mimicked by general block of calcium entry, obtained by culturing in media
lacking calcium, or by decreasing SR calcium release by addition of micromolar
ryanodine. In addition, L-type calcium channel block only perturbs morphology in
the earlier embryonic stage when the heart is undergoing septation and
morphogenesis, not in the fetal stage when the heart is exclusively undergoing
proliferation and growth. A probable explanation for this differential effect on
morphogenesis is that these two stages of development vary greatly in their
genetic programming. One example is the expression of the transcription factor
GATA4. A role for GATA4 in the fetal E16 heart has not been established.
However, GATA4 is expressed in early embryonic development and plays an
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essential role in ventral morphogenesis and cardiomyocyte proliferation near E10
[88-89]. Previous work shows that L-type calcium channel block leads to a loss of
GATA4 expression in the ventricle of E10 mice [87]. Therefore, it is possible that
the effects of L-type calcium channel block observed in the explanted heart
experiment are in part due to the loss of GATA 4 expression. In fact, embryonic
mice with an inducible GATA4 deletion that begins at E7.5 exhibit a singular
ventricle that is similar to the morphology observed with L-type calcium channel
block of explanted hearts (Figure 2.1; [88]). GATA4 is not known to be regulated
by the L-type calcium channel. However, Dr. Elizabeth Schroder performed a
microarray of E10 hearts treated for 48 hours with 1µM verapamil that showed a
trend towards decreasing GATA4 expression (p=0.053). Real-time RT-PCR
would need to be performed as a follow up experiment to determine if this
decrease was significant. If these findings hold, it would be interesting to see if
GATA4 over-expression could negate the effects of L-type calcium block on
embryonic heart morphogenesis. However, if GATA4 shows no change with
calcium channel block there are number of other possible genes and
transcription factors to be studied. The microarray performed by Dr. Schroder
showed significant changes in the expression of 433 genes. The greatest number
of alternatively expressed genes was involved with developmental processes,
followed by cellular communication, cellular differentiation, signal transduction,
transcription, and calcium ion transport. An interesting future study would be to
mine the microarray data for novel genes regulated by calcium that are known to
be directly involved in cardiogenesis. Approximately 85 of the 433 genes that
showed significant changes in microarray were involved with developmental
processes. Therefore, I would expect fewer than 85 genes of these genes to
have a direct and established role in cardiogenesis.
L-type calcium channel block induces pharmacological resistance that
allows for contraction. This observation was made in both the embryonic and
fetal heart, but was present in a larger percentage of embryonic hearts (Figures
2.1, 2.8). This finding was consistent with the observation made by Porter et al.
that treatment of E7.5-E8.5 embryos with pharmacological L-type calcium
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channel block for two days did not significantly alter heart rate [87]. L-type
calcium channel block resistance was not due to switching to the nifedipineresistant splice variant of CaV1.2, suggesting that another calcium-conducting
channel is involved. One possible candidate is the T-type calcium channel, which
is pharmacologically resistant to nifedipine and verapamil. The role of T-type
calcium channels in the embryonic heart is not well established, although there is
some evidence that T-type calcium channels play a role in calcium-induced
calcium release [104]. There are two types of T-type calcium channels expressed
in the developing heart, CaV3.1 and CaV3.2 [5, 7]. Microarray and real time RTPCR performed by Dr. Schroder revealed an increase in CaV3.1 expression with
L-type calcium channel block (data not shown). An increase in CaV3.1 mRNA
and protein was also observed in the CaV1.2 knockout model [97]. However,
there was no significant change in T-type calcium channel current with CaV1.2
knockout compared to control [6]. There was also no significant change in T-type
calcium channel current observed in the CaVβ2 knockout mouse [91]. These
findings suggest that although CaV3.1 expression is increased with L-type
calcium channel perturbation, it does not translate to a change in CaV3.1
function. Therefore, upregulation of CaV3.1 may not be an explanation as to how
embryonic hearts can retain their ability to contract in the presence of L-type
calcium channel block. Another possible candidate is a nifedipine-resistant
calcium channel that has been identified and characterized in neonatal rat
cardiomyocytes [105-107]. Little is known about this channel other than its
electrophysiological properties. Similar to the L-type calcium channel, the
nifedipine-resistant calcium channel is activated in the same voltage range and
its current density is increased when barium is substituted for calcium as the
charge carrier. However, the steady-state inactivation is negatively shifted by
16mV compared to the L-type calcium channel [106]. A future experiment would
be to perform whole-cell patch clamp to determine if cardiomyocytes treated for
48 hours with nifedipine displayed an increase in nifedipine-resistant calcium
channel current density.
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L-type calcium channel block, in addition to inducing nifedipine resistance,
also caused a significant decrease in SR load and SR leak in E10
cardiomyocytes. This finding is not consistent with the CaVβ2 knockout mouse,
which showed no significant change in SR load at E10.5 [91]. The differential
effects on SR load may be due to the retained presence of approximately 70% of
L-type calcium channel current density in CaVβ2 knockout mice compared to
control. This L-type calcium channel current is sensitive to the drug isradipine,
which is in the same class of dihydropyridines as nifedipine. It is possible that the
nifedipine-resistant E10 cardiomyocytes have a decrease in calcium entry into
the cardiomyocyte, which in turn, would decrease SR load. However, trans-SL
diastolic calcium entry is unchanged in nifedipine-resistant cardiomyocytes.
While this is not a direct measurement of calcium entry into the cardiomyocyte, it
may be used as an index of calcium entry as it is nifedipine-sensitive (Figure
2.3). Further evidence that the change in SR load observed in E10
cardiomyocytes may not be due entirely to a decrease in calcium entry is
provided by E16 cardiomyocytes that show no significant change in SR load with
48 hour nifedipine treatment (Figure 2.8). If a decrease in calcium entry was the
sole explanation for the change in SR load, then E16 cardiomyocyte should also
exhibit a decrease in SR load. However, to directly address the question of
whether or not a decrease in calcium entry is the reason for the decrease in SR
load in E10 cardiomyocytes, a future experiment should be performed. E10
cardiomyocytes treated for 48 hours with nifedipine should be subjected to
increased extracellular bath calcium, which has previously been shown to
increase both calcium entry and diastolic calcium levels [98]. If a decrease in
calcium entry is the reason for a decrease in SR load, then I would predict that
raising extracellular bath calcium would significantly increase SR load in E10
nifedipine-treated cardiomyocytes. If there was no change in SR load with
increased extracellular calcium, then I would suggest that the change may be
due to differential expression of genes involved in regulation of SR calcium, such
as RYR and SERCA.
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Figure 2.1 The effect of pharmacological L-type calcium channel block
(LTCCB) on E10 in vitro cardiogenesis. A) Representative photographs of E10
hearts treated with the LTCC antagonist nifedipine or verapamil or treated with
nominal calcium free media. The black and white arrows denote the sulcus at the
atrioventricular canal (AVC) and at the site of interventricular septation (IVS)
respectively. (White Scale bar = 200mm) B) LTCCB dose dependently decreases
the percentage of hearts that contain a sulcus at the AVC or IVS at 48 hours. C)
LTCCB initially stops contraction in all hearts (as denoted by an arrow). However,
by 24 hours contraction resumes in the presence of LTCCB at all doses except
for 100µM nifedipine. All hearts stopped beating in Ca-free media.
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Figure 2.2 Representative calcium imaging traces from embryonic day 10
cardiomycoytes. Cardiomyocytes were first placed in physiological salts
solution (PSS) that included 1.8mM calcium. This allowed for the measurement
of spontaneous calcium transients. Extracellular calcium was removed by
washing in a PSS solution containing no calcium and 5mM of the calcium
chelator EGTA (0 Ca/EGTA). This caused an abrupt cessation of spontaneous
transients and cytosolic calcium levels relaxed to a new steady-state within
approximately 8 seconds. Trans-SL diastolic calcium entry was measured by
calculating the difference in calcium levels between the 0 Ca/EGTA level and the
mean diastolic level measured in PSS (labeled ‘i’). Next, SR calcium load was
measured by adding 50mM caffeine for a 25 second interval; the amplitude of the
cytosolic calcium transient (labeled ‘ii’) acts as an index of SR load.
Approximately 20 seconds post caffeine application cytosolic calcium reached a
new steady-state level. The difference between this steady-state calcium level
and the steady-state calcium level achieved upon initial application of 0Ca/EGTA
is an index of SR calcium leak (labeled ‘iii’).
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Figure 2.3 L-type calcium channel block (LTCCB) for 48 hours induces
LTCCB resistance in a sub-population of E10 ventricular cardiomyocytes
(VMs). Application of acute 10µM nifedipine to vehicle treated VMs (No Drug;
n=9) significantly decreased trans-sarcolemmal diastolic calcium entry (A),
sarcoplasmic
reticulum
(SR)
load
(B),
and
SR
leak
(C)
(*p<0.02;ANOVA).Treatment of E10 VMs for 48 hours with 10µM nifedipine
resulted in a subpopulation of VMs that were quiescent (48H-Q; n=11) and a
subpopulation of VMs that exhibited spontaneous transients (48H-ST; n=4).
Acute nifedipine application significantly decreased trans-sarcolemmal diastolic
calcium entry in 48H-Q VMs but not in 48H-ST VMs. However, acute nifedipine
did not significantly change SR load or SR leak in either population.
(*p<0.02;ANOVA)
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Figure 2.4 There is no interdependence between trans-sarcolemmal diastolic
calcium entry and spontaneous transient frequency (A) or sarcoplasmic reticulum
load and spontaneous transient frequency (B) in E10 ventricular myocytes.
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Figure 2.5 Pharmacological ryanodine receptor (RYR) block does not
visibly alter E10 in vitro cardiogenesis. A) Representative photographs of E10
hearts treated with the RYR antagonist ryanodine. The black and white arrows
denote the sulcus at the atrioventricular canal (AVC) and at the site of
interventricular septation (IVS) respectively. (Scale bar = 200µm) B) Ryanodine
decreases the rate of E10 heart contraction (Control n=19; Ryanodine n=19;
*p<0.01; t-test).

30

Figure 2.6 Alternative
F
A
e splicing of Exon 8 of CaV1.2
2 is not inffluenced by
b Lty
ype calcium channel block. E1
10 hearts were
w
treate
ed for 48 ho
ours with 10µM
nifedipine orr vehicle (ccontrol). Co
ontrol E10 hearts
h
only contain the
e Exon 8 splice
s
variant, as is evident by
b the abilitty of BamH
HI, but not HaeIII, to cleave
c
the PCR
product; 10m
mM nifedipine does no
ot alter spliccing. “S” ind
dicates stan
ndard.

31

Figure 2.7 Pharmacological L-type calcium channel block (LTCC block)
does not visibly perturb E16 in vitro cardiogenesis. A) Representative
photographs of E106hearts treated with the LTCC antagonist nifedipine . (White
Scale bar = 5mm) B) LTCC block dose dependently decreases the percentage of
contracting hearts at 24 hours. By 48 hours, some of the hearts have developed
nifedipine resistance and have resumed contraction.
32
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Figure 2.8 E16 ventricular cardiomyocytes (VMs) treated with 48 hour Ltype calcium channel block exhibit resistance. E16 VMs were treated with
10mM nifedipine for 48 hours and subjected to the same calcium imaging
protocol as described in Fig 2. Similar to the 48H-ST population of E10 VMs
shown in Fig 2, application of acute 10µM nifedipine to 48H treated E16
ventricular myocytes did not significantly alter trans-sarcolemmal calcium entry
(A), SR load (B), or SR leak (C). (No Drug, n=6; 48H Nifedipine, n=6; *p<0.05; ttest)
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Chapter 3: CCt Localizes to the Nucleus in Developing Cardiomyocytes and
Regulates CaV1.2 Transcription

3.1 Introduction
Chapter 2 provided evidence that pharmacological block of the L-type
calcium channel disrupts morphogenesis of the E10 heart. Altering intracellular
calcium by blocking the RYR receptor on the SR or by culturing hearts in the
absence of extracellular calcium did not have the same effects on E10 cardiac
development as L-type calcium channel block. What is unknown is how
pharmacological L-type calcium channel block can be directly regulating
morphogenesis of the E10 heart. If pharmacological block were disrupting
morphogenesis simply by perturbing intracellular calcium and calcium handling,
then culturing hearts in the absence of calcium or in the presence of RYR
receptor block should have produced a perturbed morphology similar to L-type
calcium channel block. However, this was not the case. This observation
suggests that the L-type calcium channel has an alternative mechanism by which
it can regulated E10 heart morphogenesis. Recently it was shown that, in
neurons, the cleaved portion of the CaV1.2 carboxyl terminus (CCt) localizes to
the nucleus and regulates gene transcription; moreover, localization of CCt in the
neuron is regulated by pharmacological L-type calcium channel block [35]. In the
heart, CaV1.2 is also proteolytically cleaved, producing CCt [34, 108]. However, it
is unknown if CCt is capable of localizing to the nucleus and regulating
transcription in cardiomyocytes. Therefore, I tested the hypothesis that CCt
localizes to the nucleus in cardiomyocytes, and that CCt localization is regulated
by L-type calcium channel block. If CCt is indeed localized to the nucleus, and if
this localization is regulated by L-type calcium channel block, then it could
provide the basis for a mechanism by which the L-type calcium channel directly
regulates embryonic heart morphogenesis.
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3.2 Materials and Methods
3.2.1 Cell Culture
E16 cardiomyocytes were isolated and cultured as described in Section
2.2.1. HEK-293 cells were cultured in the same media described in Section 2.2.1.
3.2.2 Vector Construction
A pEGFP-C1 plasmid containing the rabbit CaV1.2 sequence between
amino acids 1507-2171 (eGFP1507-2171; a kind gift from Dr. Chunyan Pang)
was used as a template to amplify the sequence corresponding to amino acids
1821-2171 via PCR. The amplified PCR product was ligated into the multiple
cloning site of pEGFP-C1 and verified by sequencing (eGFP1821-2171; Davis
Sequencing). pEGFP-C1 containing the sequence from rabbit CaV1.2 amino
acids 1906-2171 (eGFP1906-2171) and pcDNA3.1+Zeo3HAa containing the
rabbit CaV1.2 amino acid sequence from 1906-2171 (HA1906-2171) were also
generously provided by Dr. Chunyan Pang. Mutations of Serine 1928 were made
in the eGFP1821-2171 construct were made using the QuikChange II SiteDirected Mutagenesis Kit (Strategene). A phosphodeficient mutant, S1928A, was
made by mutating serine (TCC) to an alanine (GCT). A phosphomimetic mutant,
S1928E, was made by mutating serine (TCC) to glutamic acid (GAG). Sitespecific mutation was verified by sequencing of the entire coding region of the
vector (David Sequencing).
3.2.3 Translocation Assay
E16 cardiomyocytes were transfected twenty-four hours post-isolation
using Lipofectamine2000 (Invitrogen). Twenty-four hours later, cells were either
treated with drug or immediately fixed with 4% paraformaldehyde, permeabilized
with 0.5% Triton, and blocked with 1% BSA in PBS. Cardiomyocytes were
stained with mouse sarcomeric anti-α-actinin (Sigma) and Alexa Fluor-594 goat
anti-mouse IgG1 (Invitrogen) to identify cardiomyocytes and mounted with Vecta
Shield with DAPI (Vector Laboratories) to identify nuclei. A LSM 5 Live (Zeiss)
was used to obtain confocal images of 1µm thickness focused on the center of
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the nuclei. Nuclear and cytosolic fluorescence was quantified using ImageJ
(available at http://rsb.info.nih.gov/ij; developed by Wayne Rasband, National
Institutes of Health, Bethesda, MD) with the LSM Toolbox. The area within the
nucleus and cytosol containing the greatest fluorescent intensity was used to
measure the nuclear to cytosolic ratio. Representative images were obtained
using a Leica TSP SP5 confocal microscope.
3.2.4. Whole-Cell Calcium Imaging
E16 cardiomyocytes were transfected with eGFP, eGFP1821-2171. or
eGFP1906-2171. Whole-cell calcium imaging was performed as described in
Section 2.2.2 48 hours post-transfection.
3.2.5 Immunocytochemistry with Ab55
HEK-293 cells were transfected with eGFPCaV1.2 or eGFP1821-2171
using Lipofectamine 2000 (Invitrogen). Twenty-four to forty-eight house posttransfection, cells were fixed with 4% paraformaldehyde, permeabilized with
0.5% Triton, and blocked with 1% BSA in PBS. Cells were stained with Ab55 and
goat anti-rabbit IgG(H+L) Alexa 594 (Invitrogen) and mounted with Vecta Shield
with DAPI (Vector Laboratories) to identify nuclei. A LSM 5 Live (Zeiss) was used
to obtain confocal images.
3.2.6 Western Blot
To probe for whole-cell CaV1.2 protein, whole cell lysates were obtained
from E16 ventricular cells cultured for 48 hours with DMSO or 10μM nifedipine
using Ripa buffer. Each sample (10μg) was run out on a 7.5% SDS-Page
separating gel (Bio-Rad). Immunoblotting was performed using 2 µg/ml of affinitypurified L-type Ca2+ channel α1c-subunit polyclonal antibody (gift from Dr.
Douglas Andres) visualized with horseradish peroxidase-conjugated goat antirabbit

secondary

antibody

(Chemicon)

and

Super

Signal West

Pico

Chemiluminescence (Pierce). To confirm loading, blots were stripped using
Restore Western Blot Stripping Buffer (Pierce) and re-probed with GAPDH
monoclonal antibody (Ambion) and horseradish peroxidase-conjugated goat anti-
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mouse secondary antibody (Invitrogen). An Epson Perfection 1650 was used to
scan the immunoblots, and bands were quantified using densitometry (Scion
Image, Scion).
Nuclear and cytosolic protein fractions were obtained using the NE-PER
kit (Pierce). Each protein sample (60μg) was run out on a 4-15% separating
SDS-PAGE gel (Bio-Rad). Immunoblots were performed with Ab55, a custom
antibody against amino acids 2051-2064 in the carboxyl-terminus of CaV1.2
(ECM Biosciences, Versailles, KY), Pol II (Santa Cruz Biotechnology), or GAPDH
(Ambion). Blots were visualized using horseradish peroxidase-conjugated goat
secondary

antibodies

(Chemicon)

and

Super

Signal

West

Pico

Chemiluminescence (Pierce). An Epson Perfection 1650 was used to scan the
immunoblots and bands were quantified using densitometry (ImageJ, available at
http://rsb.info.nih.gov/ij; developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD).
3.2.7 Luciferase Assay
The CaV1.2 promoter reporter construct was created by Dr. Schroder and
these experiments were performed primarily by Dr. Schroder. Five independent
wells containing E16 ventricular cardiomyocytes were transfected within 24 hours
of dispersal with pGL3-CaV1.2 or the promoter-lacking vector called pGL3-Basic.
To test for the effect of sustained channel block (24 hours), 1μM verapamil was
added to a sub-population of cells 24 hours post-transfection. Luciferase activity
was first normalized to renilla for all conditions. Luciferase/renilla level was
determined in cells transfected with pGL3-basic and this value was subtracted
from luciferase/renilla value in cells transfected with pGL3-CaV1.2.
3.2.8 Real-Time RT-PCR
For Real-Time RT-PCR, RNA was isolated using the RNAqueous-4PCR
Kit (Ambion) and genomic DNA was removed using DNase I (Ambion). cDNA
was prepared using the SuperScript First Strand Synthesis System for RT-PCR
(Invitrogen), quantified using the Quant-iT OliGreen ssDNA Assay Kit
(Invitrogen), and stored at -20oC. Real-time RT-PCR was performed using 10ng
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of cDNA and the TaqMan Gene Expression Assay with primers for CaV1.2,
CaV1.3, and CaV3.1 (Applied Biosystems). Samples were cycled and analyzed
following Applied Biosystems Gene Expression Assay Protocols.

3.3 Results
3.3.1 CCt Localizes to the Nucleus in Cardiomyocytes
Previous work shows that in neurons CCt localizes to the nucleus via a
nuclear retention domain located between amino acids 1821-1910 (rabbit
sequence) [35]. Therefore, two constructs were used to test the ability of CCt to
localize to the nucleus in cardiomyocytes. The first construct expresses the
cleaved full-length portion of CaV1.2 that would be predicted to localize to the
nucleus, eGFP1821-2171 [34-35]. The second construct expresses a truncated
version of CCt, which lacks the proposed nuclear retention domain, eGFP19062171 (kindly provided by Dr. Chunyan Pang). A construct expressing eGFP alone
was used as a control. E16 cardiomyocytes were transfected with one of these
three constructs and the nuclear normalized to cytosolic eGFP signal intensity
was measured (Figure 3.1). E16 cardiomyocytes expressing eGFP alone show a
signal in both the nucleus and cytosol. The nuclear intensity is approximately
twice that of the cytosol. E16 cardiomyocytes over-expressing eGFP1821-2171
have a nuclear signal intensity that is significantly increased from eGFP alone,
suggesting that CCt is able to localize to the nucleus. Surprisingly, eGFP19062171, which should lack a nuclear retention signal, localized almost exclusively to
the nucleus. These findings provide evidence that CCt localizes to the nucleus in
cardiomyocytes and also suggests that regulation of CCt nuclear localization may
differ between cardiomyocytes and neurons.
CCt has also been shown to form a complex with cleaved CaV1.2 and act
as an autoinhibitory domain that essentially decreases CaV1.2-mediated calcium
entry in an HEK over-expression system [34]. However, cardiomyocytes overexpressing eGFP1821-2171 or eGFP1906-2171 exhibited no significant change
in spontaneous calcium transient frequency compared to eGFP over-expressing
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cardiomyocytes (Figure 3.4A). This raises an interesting conundrum. If CCt acts
as an autoinhibitor of CaV1.2, then over-expression of CCt should decrease
calcium-entry via CaV1.2 and either decrease the frequency of or completely halt
spontaneous calcium transients. This raises the question of whether or not CCt
over-expression is altering calcium handling. To address this question, whole-cell
calcium imaging was used to test the effect of CCt over-expression on
cardiomyocyte calcium handling. Over-expression of eGFP1821-2171 for 48
hours significantly increased SR load, with a trend toward increased SR leak and
increased amplitude of spontaneous transients (Figure 3.4B). There was no
significant change in trans-SL diastolic calcium entry. Over-expression of
eGFP1906-2171 had a similar, but more pronounced effect compared to
eGFP1821-2171. SR load and leak were both significantly increased with
eGFP1906-2171 over-expression, with a trending increase in spontaneous
transient amplitude. There was no change in trans-SL diastolic calcium entry.
These findings differ from the effects of 48 hour nifedipine in E10 and E16
cardiomyocytes (Figures 2.3 and 2.8). In E10 cardiomyocytes, nifedipine
significantly decreased SR load and leak. In E16 cardiomyocytes, nifedipine had
no significant effect on SR load and leak. The differences in SR load between the
over-expression model and the nifedipine-treated models suggests that CCt may
be having an alternative function in cardiomyocytes that is in addition to or
independent of regulating CaV1.2 calcium current; CCt may be localizing to the
nucleus and acting as a transcription factor in cardiomyocytes.
3.3.2 CCt Nuclear Localization is Regulated by L-type Calcium Channel
Block
Over-expressed CCt localizes to the nucleus in cardiomyocytes. To test
the hypothesis that CCt nuclear localization is regulated by pharmacological Ltype calcium channel block, I first attempted to perform fluorescence after
photobleaching (FRAP) experiments. FRAP experiments were utilized by
Gomez-Ospina et al. to test the rate of nuclear localization of over-expressed
CCt in Neuro2A cells [35]. Briefly, Gomez-Ospina et al. over-expressed CaV1.2
with a carboxyl-terminal YFP tag (CaV1.2-YFP) in Neuro2A cells, photobleached
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the nucleus, and then measured the time it took for fluorescent YFP to reappear
in the nucleus. From these experiments they concluded that it took approximately
300 seconds for the CaV1.2-YFP to repopulate the nucleus. Purportedly, since
CaV1.2 was YFP tagged at the carboxyl-terminus, it was only the cleaved
carboxyl-terminal portion of the channel that localized to the nucleus, not the
entire CaV1.2 channel. Based on their findings I hypothesized that if L-type
calcium channel block regulates trafficking of CCt, then L-type calcium channel
block, in comparison to control, should alter the ability of over-expressed CCt to
re-localize to the nucleus after photobleaching. To test the feasibility of this
experiment, I first over-expressed eGFP or eGFP1507-2171 (kindly provided by
Dr. Chunyan Pang) in E10 cardiomyocytes and performed FRAP. The use of
eGFP1507-2171 was dictated by the fact that it contains the purported nuclear
retention domain described by Gomez-Ospina et al., it localizes to the nucleus in
cardiomyocytes (Figure 3.2), and that the eGFP1821-2171 construct was not
available at the time. The FRAP experiments revealed that the time course of
nuclear localization of eGFP or eGFP1507-2171 after photobleaching were the
same. It took approximately 60 seconds for nuclear fluorescent intensity to reach
pre-bleach levels with both constructs. This finding contradicts those by GomezOspina et al., where they reported that YFP alone localized to the nucleus at a
faster rate than CaV1.2-YFP. The fact the eGFP and eGFP1507-2171 localize to
the nucleus at the same rate suggests that at least on the order of seconds, the
eGFP tag attached to the 1507-2171 piece regulates its nuclear transport.
Preliminary FRAP experiments revealed that on the order of seconds,
nuclear localization of eGFP1507-2171 was regulated by its eGFP tag. However,
this finding does not exclude the possibility that nuclear localization of CCt is
regulated on a longer time-scale, for example on the order of hours. As shown in
Figure

3.1,

nuclear

localization

of

over-expressed

eGFP1821-2171

or

eGFP1906-2171 is significantly increased compared to eGFP alone at 24 hours.
This suggests that nuclear localization of CCt itself is regulated over a period of
24 hours. If the eGFP tag alone was responsible for CCt nuclear localization,
then there would be no significant difference in nuclear localization between

41

eGFP, eGFP1821-2171, or eGFP1906-2171. In light of this observation, I chose
to study the effects of 24 hour L-type calcium channel block on over-expressed
CCt nuclear localization in cardiomyocytes. E16 cardiomyocytes over-expressing
eGFP, eGFP1821-2171, or eGFP1906-2171 were treated for 24 hours with 10µM
nifedipine. Treatment with pharmacological L-type calcium channel block
significantly decreased nuclear localization of eGFP1821-2171 (Figure 3.3A),
but did not change eGFP localization. This suggests that L-type calcium channel
block regulates CCt nuclear localization. However, L-type calcium channel block
had no effect on eGFP1906-2171 nuclear localization. To confirm that the effects
of nifedipine on eGFP1821-2171 nuclear localization were L-type calcium
channel block specific, E16 cardiomyocytes over-expressing eGFP1821-2171
were also treated with 1µM verapamil for 24 hours. L-type calcium channel block
by both nifedipine and verapamil significantly decreased nuclear localization of
CCt, suggesting that the alteration in eGFP1821-2171 nuclear localization is Ltype calcium channel block specific (Figure 3.3B).
Nuclear localization of over-expressed eGFP1821-2171 was altered by Ltype calcium channel block. However, this does not necessarily mean that
endogenous CCt is altered by L-type calcium channel block in cardiomyocytes. In
order to study the effects of calcium channel block on endogenous CCt nuclear
localization, a custom antibody against the distal portion of CCt, Ab55, was used.
To test the ability of Ab55 to probe for endogenous CCt in individual cells,
immunocytochemistry was performed. HEK-293 cells were used as a negative
control since they have very little CaV1.2 [109]. For positive controls, full-length
eGFPCaV1.2 (green) or eGFP1507-2171 (green) were over-expressed in HEK293 cells. Ab55 association was visualized using a secondary antibody that
excites at 594nm (red). Figure 3.5A shows representative confocal images from
HEK-293 cells over-expressing eGFPCaV1.2 (top) or eGFP1507-2171 (bottom).
Ab55 interacted with an unknown epitope in HEK-293 cells in addition to
recognizing eGFPCaV1.2 over-expressing HEK-293. Additionally, Ab55 did not
recognize eGFP1507-2171 in all over-expressing HEK-293 cells. These findings
indicate that Ab55 is not suitable for immunocytochemistry. Next, Ab55 was
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tested for its ability to recognize CCt via immunoblot by Dr. Schroder (Figure
3.5B). Full-length CaV1.2 or eGFP1821-2171 was over-expressed in tsA-201
cells. Ab55 detected full-length CaV1.2 (~240kDa) and over-expressed CCt
(~37kDa). Probing with an eGFP-specific antibody detected a similarly sized
band as Ab55 (data not shown). In E16 cardiomyocytes, Ab55 detected a band
at ~37kDa that increased in intensity with HA1906-2171 over-expression. A
similarly sized band was detected with anti-HA antibody (data not shown). A
~37kDa band was also detected in adult ventricular myocytes with Ab55.
Additionally, probing with an antibody against the II-III linker of CaV1.2 shows that
E16 and adult ventricular myocytes only express the proteolytically cleaved
CaV1.2 (~190kDa) [29-32]. These findings indicate that Ab55 is able to detect
endogenous CCt via immunoblot.
To test the effects of L-type calcium channel block on CCt localization in
the cardiomyocytes, Ab55 was used to probe western blots of cytosolic and
nuclear protein fractions from E16 cardiomyocyte cultures. Cultured E16
cardiomyocytes were treated for 24 hours with 10µM nifedipine, 1µM verapamil,
or a calcium free solution containing 0.3mM EGTA (0Ca+0.3mM EGTA). Western
blot confirmed that the percent of nuclear CCt probed with Ab55 significantly
decreased

with

nifedipine

treatment

(Figure

3.6).

Verapamil

and

0Ca+0.3mMEGTA had similar but non-significant effects. This may have been
due to the inherent confounds of this experiment, which is the availability of only
a relatively small amount of tissue, ultimately leading to low protein yields. These
results provide further support that nuclear localization of CCt is regulated by
calcium in developing cardiomyocytes.
3.3.3 Phosphomimetic Mutation of Serine 1928 Significantly Decreases CCt
Nuclear Localization
Calcium

regulates

endogenous

and

over-expressed

CCt

nuclear

localization in embryonic cardiomyocytes. However, the question remains of the
exact mechanism regulating CCt localization. Nucleocytoplasmic transport of
transcription factors can be regulated by numerous mechanisms, including
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phosphorylation and dephosphorylation [110]. It is established that CCt can be
phosphorylated at Serine 1928 by both β-adrenergic receptor activated PKA and
α-adrenergic receptor activated PKC [47-48]. Conversely, CCt can also be
dephosphorylated at Serine 1928 by protein phosphatase 2A (PP2A) [111].
Therefore I hypothesized that mutation of Serine 1928 would alter overexpressed CCt nuclear localization in embryonic cardiomyocytes. Mutations were
made in the eGFP1821-2171 vector. A phosphodeficient mutation was created
by mutating Serine 1928 to an alanine (S1928A) and a phosphomimetic mutation
was created by mutating Serine 1928 to glutamic acid (S1928E). Nuclear
localization of over-expressed eGFP1821-2171, S1928A, and S1928E was
compared in E16 cardiomyocytes. S1928E showed a significant decrease in
nuclear localization compared to eGFP1821-2171 (Figure 3.7). To confirm that
phosphorylation of Serine 1928 decreased nuclear localization of CCt,
eGFP1821-2171 over-expressing cardiomyocytes were treated with 1µM
isoproterenol for 10 minutes. Treatment with isoproterenol should cause
phosphorylation of Serine 1928 via PKA. However, isoproterenol treatment did
not significantly alter CCt nuclear localization (data not shown). One possible
explanation for this lack of effect is that a majority of over-expressed eGFP18212171 is already phosphorylated at Serine 1928; therefore, β-adrenergic
stimulation has no large effect on nuclear localization. This may explain why
over-expressed CCt is not exclusively localized to the nucleus in untreated
cardiomyocytes. A future experiment to test this supposition would be to acutely
treat cardiomyocytes over-expressing eGFP1821-2171 with a PKA and/or PKC
inhibitor in order to block phosphorylation of Serine 1928. I hypothesize that
acute treatment with a PKA or PKC inhibitor would significantly increase
eGFP1821-2171 CCt nuclear localization.
3.3.4 CCt Regulates CaV1.2 Expression in Fetal Cardiomyocytes
The previous data suggests that CCt is capable of localizing to the
nucleus in cardiomyocytes. However, the question remains of whether or not CCt
nuclear localization has functional relevance in the cardiomyocyte. To begin
answering this question, I chose to test the hypothesis that, similar to neurons,
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CCt functions as a transcription factor in cardiomyocytes. An intriguing, potential
transcriptional target of CCt is CaV1.2. Previous work published by Dr. Schroder
showed that forty-eight hour treatment of adult mice with the L-type calcium
channel blocker verapamil significantly increased CaV1.2 expression [112]. My
data provides evidence that in embryonic cardiomyocytes, twenty-four hour
pharmacological L-type calcium channel block decreases nuclear localization of
CCt. Therefore it is possible that there is a correlation between CaV1.2
expression and CCt nuclear localization, and that, furthermore, CCt regulates
CaV1.2 expression. To begin establishing this correlation, I first wanted to confirm
that L-type calcium channel block was indeed increasing CaV1.2 expression in
the developing heart. E16 cardiomyocytes were treated with 10µM nifedipine for
48 hours. At 48 hours, CaV1.2 protein and CaV1.2 mRNA were both significantly
increased (Figure 3.8A,B), confirming that L-type calcium channel block
increases CaV1.2 expression in the fetal heart. Next, to begin to determine if CCt
is capable of regulation CaV1.2 expression, the effects of CCt over-expression on
CaV1.2 mRNA were measured. At 72 hours, over-expression of eGFP1821-2171
significantly decreased CaV1.2 mRNA expression compared to eGFP overexpressing controls (Figure 3.9B). These findings support the postulate that CCt
is capable of regulating CaV1.2 message, and furthermore, suggest that CCt may
be directly regulating CaV1.2 transcription.
To test the hypothesis that CCt directly regulates CaV1.2 transcription,
luciferase assays were first performed to determine if CCt can regulate the
CaV1.2 promoter. These experiments were graciously performed by Dr.
Schroder. First, Dr. Schroder tested whether or not L-type calcium channel block
increased CaV1.2 promoter activity in correlation with the increase in CaV1.2
mRNA and protein that I observed. Figure 3.8C shows that 48 hour treatment
with the L-type calcium channel inhibitor verapamil significantly increased CaV1.2
promoter activity in E16 cardiomyocytes compared to vehicle treated control.
These findings correlate with the observed increase in CaV1.2 mRNA and protein
expression with verapamil treatment (Figures 3.8A,B). Next, Dr. Schroder tested
whether or not over-expressed CCt decreased CaV1.2 promoter activity in
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correlation with the decrease in CaV1.2 mRNA that I observed. Figure 3.9A
shows that over-expression of CCt significantly decreased CaV1.2 promoter
activity compared to over-expressed eGFP control. These data provided by Dr.
Schroder suggest that CCt is capable of regulating the CaV1.2 promoter to
repress transcription of CaV1.2; furthermore, Dr. Schroder has published
Chromatin immunoprecipitation (ChIP) data showing that CCt is able to bind to
the CaV1.2 promoter [29]. Together, these findings provide evidence that, similar
to neurons, CCt is capable of acting as a transcription factor in cardiomyocytes.

3.4 Discussion
One of the primary findings in this chapter is that over-expressed CCt and
endogenous CCt localize to the nucleus in cardiomyocytes, and that this nuclear
localization is regulated by L-type calcium channel block. However, there are
some differences between these findings and the published work of CCt’s role in
neurons [35]. First, it was shown in neurons that a nuclear retention signal is
located between amino acids 1821-1910. However, in cardiomyocytes, overexpression of eGFP1906-2171, which lacks the purported nuclear retention
domain, had more pronounced nuclear localization than eGFP1821-2171 (Figure
3.1). One possible explanation for this difference is that Gomez-Ospina et al.
performed their experiments to determine the nuclear retention domain in human
embryonic kidney (HEK-293) cells. HEK-293 cells have a very small calcium
current density and lack the calcium handling properties and spontaneous activity
of cardiomyocytes [109]. While their findings are valid in HEK-293 cells, they may
not necessarily translate to a cardiomyocyte where calcium regulation is likely
overriding a lack of the purported nuclear retention domain. In fact, in
cardiomyocytes the region between amino acids 1821-1906 may act as a
calcium-regulated nuclear targeting domain. L-type calcium channel block
decreased nuclear localization of eGFP1821-2171, but had no effect on
eGFP1906-2171. To identify the potential calcium-regulated nuclear targeting
domain, constructs would need to be made that successively deleted regions
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starting from amino acid 1821. If the domain was identified, it would be
interesting to test mutations of the amino acids in that domain to see if those
mutations would alter the ability of L-type calcium channel block to regulate
eGFP1821-2171 nuclear localization. A second difference between my work and
that performed by Gomez-Ospina et al. was the effect that L-type calcium
channel block had on CCt nuclear localization. Gomez-Ospina et al. reported an
increase in CCt nuclear localization in cortical neurons with L-type calcium
channel block. I observed a decrease in CCt nuclear localization with L-type
calcium channel block in cardiomyocytes. The experiments performed by
Gomez-Ospina et al. utilized immunocytochemistry to look at CCt localization in
cortical neurons. In contrast, the experiments in this chapter were initially
performed in E10 cardiomyocytes using over-expressed eGFP tagged CCt. A
limitation to over-expression experiments is that expression levels cannot be
controlled in individual cells. It is possible that eGFP tagged CCt was overexpressed at a level that overwhelmed the ability of individual cardiomyocytes to
fully regulate CCt localization. However, population differences were seen in
eGFP tagged CCt nuclear localization in response to L-type calcium channel
block and zero calcium (Figure 3.2). These findings corresponded to the results
obtained via western blot where antibody was used to measure endogenous CCt
nuclear localization in E16 cardiomyocytes (Figure 3.4). Therefore, while the
findings in embryonic and fetal cardiomyocytes differ to those in cortical neurons,
they are robust and suggest that the mechanisms controlling CCt nuclear
localization may differ between the two cell types.
Another finding in this chapter that differs from the current literature is that
over-expression of CCt in E16 cardiomyocytes does not alter calcium handling in
a way that is consistent with L-type calcium channel block. Hulme et al. have
shown that an over-expressed distal CCt construct (based on the rabbit
sequence from amino acid 1822-2171) associates with and inhibits overexpressed CaV1.2 channels truncated at amino acid 1821 in tsA-201 cells [34].
However, Hulme et al. did not explore the effects of over-expressing distal CCt in
cardiomyocytes. There is evidence to support that CCt is associates with the
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channel in intact cells [32]. Therefore, it is possible that in E16 cardiomyocytes, a
majority of native CCt remains associated with CaV1.2; only a small percentage
of native CCt localizes to the nucleus. Therefore, native CCt would already be
regulating CaV1.2 channel function in cardiomyocytes, and over-expressed CCt
would have little to no additional effect. One future experiment that could be
performed to test this supposition would be to over-express CCt in
cardiomyocytes and measure ICa,L to see if it is altered. I predict that overexpression of CCt in cardiomyocytes would not alter ICa,L.
In this chapter, evidence was provided that CCt nuclear localization is
regulated by calcium and L-type calcium channel block in cardiomyocytes, and
that CCt is capable of regulating transcription, specifically transcription of CaV1.2.
Chapter 2 showed that L-type calcium channel block perturbs embryonic
morphogenesis. It is possible that L-type calcium channel block mediates its
effects on cardiogenesis, in part, by decreasing CCt nuclear localization. Since
CCt is capable of acting as a transcription factor, decreasing CCt nuclear
localization could potentially alter the expression of genes that are essential for
heart development. Based on this assumption, I hypothesized that overexpression of CCt would negate the effect of L-type calcium channel block on
heart development. I attempted to transfect hearts with eGFP1821-2171 in order
to test this hypothesis. However, I only observed eGFP1821-2171 positive cells
in small regions of the heart, and the regions transfected were never identical
between hearts. Therefore these experiments would need to be repeated in a
model where CCt expression could be regulated throughout the heart. An ideal
model would be a mouse that had a cardiac-specific deletion of amino acids of
1822-2171 of CaV1.2. In this model, CaV1.2 would still be expressed, but not the
CCt portion of CaV1.2. I hypothesize that this CCt deletion mouse would exhibit
perturbed heart development, similar to that seen with L-type calcium channel
block. I would also hypothesize that this deletion would be embryonic lethal since
mice with disrupted expression of the entire CaV1.2 channel exhibit embryonic
lethality[6]. Therefore, I would ideally want to make a mouse with an inducible,
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cardiac-specific deletion of CCt so the effects of CCt deletion could be measured
throughout development and into adulthood.
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Figure 3.1 Nuclear localization of over-expressed CCt in E16
cardiomyocytes. A) Representative confocal images of E16 cardiomyocytes
over-expressing CCt. α-actinin (red) positive cells are cardiomyocytes. B)
eGFP1821-2171 and eGFP1906-2171 are both nuclear localized when overexpressed in E16 ventricular cardiomyocytes. (t-test performed)
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Figure 3.2 eGFP1507-2171 localizes to the nucleus in E16 cardiomyocytes.
Representative confocal images of E16 cardiomyocytes over-expressing CCt.
Cells with positive α-actinin (red) staining are cardiomyocytes.
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Figure 3.3 L-type calcium channel block decreases over-expressed CCt
nuclear localization in E16 cardiomyocytes. A) 10µM Nifedipine treatment for
24 hours significantly decreases the nuclear/cytosolic intensity of over-expressed
eGFP1821-2171. Nifedipine had no effect on the localization of over-expressed
eGFP or eGFP1906-2171. B) Treatment with nifedipine or verapamil for 24 hours
significantly decreased the nuclear/cytosolic intensity of eGFP1821-2171. (t-test
performed)
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Figure 3.4 CCt over-expression does not alter spontaneous calcium
transient amplitude or trans-sarcolemmal diastolic calcium entry in E16
cardiomyocytes. A) CCt over-expression had no significant effect on
spontaneous calcium transient amplitude, or trans-sarcolemmal calcium entry.
CCt over-expression significantly increase sarcoplasmic reticulum calcium load
and eGFP1906-2171 over-expression significantly increased sarcoplasmic
reticulum calcium leak (*p<0.05; t-test). B) A plot of spontaneous transient
frequency and spontaneous transient amplitude indicates no interdependence
between the two under all over-expression conditions.
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Figure 3.5 Evaluation of Ab55 for immunocytochemistry and
immunoblotting. A) Representative images of HEK-293 cells transfected with
eGFPCaV1.2 and CaVβ2A (top) or eGFP1507-2171 (bottom) and stained using
Ab55 with an AlexaFluor594 (red) secondary antibody. Arrows note cells of
interest. (White scale bar = 50µm) B) Representative western blots performed by
Dr. Schroder with CCt over-expression in tsa-201 cells and E16 ventricular
myocytes, as well as adult ventricular myocytes. Western blots were probed with
Ab55 (CCt-specific antibody) and/or II-III Linker Antibody (CaV1.2-specific
antibody).
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Figure 3.6 L-type calcium channel block significantly decreases
endogenous CCt nuclear localization. E16 cardiomyocytes were cultured for
24 hours in the presence of L-type calcium channel block (nifedipine or
verapamil) or zero calcium with 0.3mM EGTA. CCt nuclear localization was
significantly decrease with nifedipine treatment (*p<0.05; t-test). CCt trended
toward a decrease with verapamil or zero calcium treatment.
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(n=25)

(n=28)

Figure 3.7 Phosphomimetic mutation of Serine 1928 significantly decreases
over-expressed CCt nuclear localization. The nuclear localization of overexpressed eGFP1821-2171 lacking a serine 1928 mutation (1821) was
compared to nuclear localization of eGFP1821-2171 containing a
phosphodeficient mutation (S1928A) or a phosphomimetic mutation (S1928E) at
Serine 1928. (t-test performed)
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Figure 3.8 L-type calcium channel block induces compensatory upregulation of CaV1.2. A) Western blot was performed on 48H 10uM nifedipine
treated E16 cardiomyocytes. CaV1.2 protein expression was quantified using
densitometry and normalized to GAPDH. 10µM nifedipine significantly increased
CaV1.2 protein compared to control. (*p=0.02; n=3 for each condition; experiment
performed by Dr. Schroder) B) CaV1.2 mRNA in E16 hearts treated with 10µM
nifedipine. (*p<0.001; n=3 for each condition; t-test) C) Luciferase assay
performed by Dr. Schroder shows that 48H 1µM verapamil significantly increased
CaV1.2 promoter reporter activity in E16 cardiomyocytes compared to vehicle.
(p=0.03; n=5 for each condition)
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Figure 3.9 eGFP1821-2171 decreases CaV1.2 promoter activity and mRNA.
A) E16 ventricular myocytes were co-transfected for 72 hours with the CaV1.2
promoter driving luciferase and either eGFP1821-2171 or eGFP only as a
control. The luciferase assay was performed by Dr. Schroder (n=3; p<0.05) B)
E16 ventricular myocytes were transfected with eGFP1821-2171. All data is
normalized to GAPDH and shown as fold difference from eGFP-only control.
(*p<0.05; t-test)
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Chapter 4: Regulation of CCt Nuclear Localization in the Adult Heart
4.1 Introduction
L-type calcium channel blockers are used clinically in the treatment of
adult hypertension, hypertension associated with preeclampsia in pregnancy,
and pediatric hypertension [113-115]. These blockers act on the L-type calcium
channels present in smooth muscles of the vasculature, ultimately causing
relaxation. L-type calcium channels are also present in the heart, however little is
known about the long-term effects of L-type calcium channel blockers on cardiac
myocytes. Sustained hypertension is a known cause of pathological cardiac
hypertrophy that can ultimately lead to congestive heart failure, coronary heart
disease, and stroke [116]. L-type calcium channel blockers are capable of
decreasing left ventricular mass in tandem with decreasing blood pressure in
patients with hypertension-induced left ventricular hypertrophy [117-119].
However, patients with chronic heart failure due to left ventricular dysfunction
exhibited a higher incidence of heart failure deterioration when treated with the Ltype calcium channel blocker nifedipine [120]. A meta-analysis of studies where
patients with coronary heart disease were treated with L-type calcium channel
block showed that mortality rate increased in a nifedipine dose-dependent
manner [121]. It is unknown exactly how calcium channel blockers are causing
beneficial effects in hypertension induced left ventricular hypertrophy, but
deleterious effects in left ventricular dysfunction or coronary heart disease. One
possibility is that L-type calcium channel blockers are acting directly on the heart
and causing changes in calcium handling and gene expression. Evidence to
support this theory was recently shown by our lab. Treatment of mice with 48
hour L-type calcium channel block (verapamil, 3mg/kg/day) induced a significant
compensatory up-regulation of CaV1.2 expression and protein levels in the heart
[112]. However, our lab was unable to establish the mechanism of this
compensatory up-regulation at the time. In Chapter 3, I provided evidence that Ltype calcium channel block decreases nuclear localization of the transcription
factor CCt in cardiomyocytes. Furthermore, Dr. Schroder provided evidence that
CCt acts as a transcriptional repressor of CaV1.2. Therefore, it is plausible that
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the observed up-regulation of CaV1.2 expression in the 48 hour verapamil treated
mice was due to a decrease in CCt nuclear localization, which relieved
repression of the CaV1.2 promoter. Therefore, in this chapter I will test the
hypothesis that L-type calcium channel block decreases CCt nuclear localization
in adult cardiomyocytes. The possibility that L-type calcium channel blockers
regulate nuclear localization of a transcription factor, CCt, in the heart has
important clinical implications. It is possible that CCt nuclear localization is
differentially regulated in left ventricular hypertrophy and left ventricular
dysfunction, explaining the differential effects of L-type calcium channel blockers
on clinical outcome.

4.2 Materials and Methods
4.2.1 Adult Ventricular Cardiomyocyte Isolation
Hearts from 8-10 week old female ICR mice were excised and perfused
via an aortic cannula with perfusion buffer (113mM NaCl, 4.7mM KCl, 0.6mM
KH2PO4, 0.6mM Na2HPO4, 1.2mM MgSO4-7H20, 12mM NaHCO3, 10mM
KHCO3, 10mM HEPES, 30mM taurine, 6mM glucose) also containing 1mM of
the contractile inhibitor 2,3-butanedione monoxime (BDM). Constant flow of the
perfusion buffer with 1mM BDM was continued until there was no visible blood
remaining in the heart. Hearts were next perfused with digestion buffer which
consisted of perfusion buffer, 20µM CaCl2, and 10µg/mL Liberase TH (Roche) for
approximately 40 minutes. Ventricle was excised and ventricular tissue was
teased apart using forceps to promote adult ventricular myocyte dissociation.
Digestion was halted placing cardiomyocytes in Stop 1 buffer (perfusion buffer,
12.5µM CaCl2, 1% fetal bovine serum) followed by Stop 2 buffer (perfusion
buffer, 12.5µM CaCl2, 5% fetal bovine). Calcium was re-introduced to adult
ventricular myocytes over a period of 30 minutes using a calcium ladder that
began at 40µM and ended at 1.8mM CaCl2. Adult ventricular myocytes were
next transferred to and maintained in Dulbecco’s Minimal Essential Media
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100μg/ml penicillin,
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100μg/mL streptomycin, and 2μM L-glutamine. Adult ventricular myocytes were
paced using field stimulation at 1Hz with 10ms durations of approximately30
volts.
4.2.2 Whole Heart Langendorff Perfusion
Hearts from 8-10 week old female ICR mice were excised and perfused
via the aorta with perfusion buffer lacking calcium (113mM NaCl, 4.7mM KCl,
0.6mM KH2PO4, 0.6mM Na2HPO4, 1.2mM MgSO4-7H20, 12mM NaHCO3,
10mM KHCO3, 10mM HEPES, 30mM taurine, 6mM glucose). Hearts were paced
at 1Hz in perfusion buffer containing 1.8mM calcium. Verapamil (1µM),
isoproterenol (1µM), phenylephrine (20µM), H-89 (1µM), and PD-98059 (20µM)
were obtained from Sigma-Aldrich. Bim-I (1µM), Cylosporine A (10µM), and KN93 (2µM) were obtained from Calbiochem. FK-506 (1µM) was obtained from
Tocris. Left ventricular free wall tissue was excised and frozen on dry ice prior to
protein isolation.
4.2.3 Nuclear and Cytosolic Protein Extraction and Western Blot
Nuclear and cytosolic protein fractions were obtained using the NE-PER
kit (Pierce). Each protein sample (60μg) was run out on a 4-15% separating
SDS-PAGE gel (Bio-Rad). Immunoblots were performed with Ab55, a custom
antibody against amino acids 2051-2064 in the carboxyl-terminus of CaV1.2
(ECM Biosciences, Versailles, KY), Pol II (Santa Cruz Biotechnology), or GAPDH
(Ambion). Blots were visualized using horseradish peroxidase-conjugated goat
secondary

antibodies

(Chemicon)

and

Super

Signal

West

Pico

Chemiluminescence (Pierce). An Epson Perfection 1650 was used to scan the
immunoblots and bands were quantified using densitometry (ImageJ, available at
http://rsb.info.nih.gov/ij; developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD).
4.2.4 Serum-Induced Hypertrophy and Translocation Assay
E16 cardiomyocytes were isolated as described in Section 2.2.1 and
cultured in media containing 10% fetal bovine serum or in media lacking serum.
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Translocation assays were performed as described in Section 3.2.3. Cell area
was measured using ImageJ.
4.2.5 Osmotic Mini Pumps and Echocardiography
These procedures were performed by Carmen Kiper. Osmotic mini pumps
from Alzet (model no. 2002, 2004) were used for delivery of isoproterenol
(Sigma, 30mg/kg/day) or vehicle (0.02% ascorbic acid) in 10-12 week old female
ICR mice. Pumps were primed overnight and then inserted into the mouse
subcutaneously for either two or three weeks. Mice were sedated with
intraperitoneal

ketamine-xyzaline

prior

to

insertion

of

the

pump.

Echocardiography was conducted using a VisualSonics ultrasound machine on
female ICR mice prior to pump insertion and at two or three weeks post pump
insertion to look for the presence of cardiac hypertrophy. Isofluorane (2ml/min)
was used to sedate the animals and their heart rate was monitored while on a
heated platform (37°C). Images were taken on the parasternal short-axis of the
left ventricle at a rate of 7mHz using a 707 transducer. Measurements were
made in M-mode. Hypertrophy was defined as an increase in the heart weight to
body weight ratio as well as an increase in left ventricular wall thickness. Visual
sonics calculates the fractional shortening and ejection fraction by the following
formulas: FS =(LVd – LVs)/LVd and EF = (LV-Vold – LV-Vols)/LV-Vold.
4.2.6 Real-Time RT-PCR
These experiments were performed as described in Section 3.2.8.
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4.3 Results
4.3.1 Calcium Regulates CCt Nuclear Localization
Isolated adult ventricular myocytes (AVMs) were first used to test the
hypothesis that L-type calcium channel block decreases nuclear localization of
CCt. The advantage of this model is that it mimics the isolated embryonic
ventricular myocytes model utilized in Chapter 3. The effect of pacing was first
tested on isolated AVMs. The hypothesis was that paced AVMs would have the
same percentage of nuclear-localized CCt as immediately excised whole left
ventricle. AVMs were isolated from 4 or 3 individual mice and paced or not paced
for 30 minutes or 90 minutes respectively. Figure 4.1 shows that pacing AVMs
for 30 minutes (black squares) significantly decreased CCt nuclear-localization
compared to freshly excised left ventricular tissue (black diamonds). AVMs from
the same hearts that were left quiescent for 30 minutes (grey squares)
consistently showed an increase in CCt nuclear localization compared to paced
AVMs (dotted lines). This finding suggests that pacing, which should increase
cardiomyocyte calcium entry compared to quiescent cardiomyocytes, decreases
CCt nuclear localization. However, the results from the 90 minute paced AVMs
tell a different story. Similar to 30 minute pacing, AVMs paced for 90 minutes
(black triangles) showed a significant decrease in CCt nuclear localization.
Conversely, AVMs from two of the 90 minute paced mice that were left quiescent
(grey triangles) showed a decrease in CCt nuclear localization that was even
greater than the 90 minute paced AVMs (dotted lines). The findings at 90
minutes suggest that pacing increases CCt nuclear localization in 2 out of 3 mice,
which contradicts the 30 minute pacing findings. In conclusion, isolated AVMs
are an unsatisfactory model for measuring CCt nuclear localization. Culturing of
isolated AVMs in and of itself alters CCt nuclear localization, which is exemplified
by 90 minute quiescent AVMs exhibiting a significant decrease in CCt nuclear
localization compared to excised left ventricular tissue. Further evidence that
isolated AVMs are an unsatisfactory model can also be seen in the large data
scatter between individual mouse AVM isolations at the 30 minute and 90 minute
time points. This large scatter is not observed in excised left ventricular tissue
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from individual mice. This difference in data scatter suggests that the quality of
each individual AVM isolation may also affect CCt nuclear localization, further
complicating this model system.
Isolated AVMs are not an ideal model system for studying CCt nuclear
localization due to inconsistent results between individual isolations and between
the times of cultures. Therefore, an alternative model was used to test the effects
of L-type calcium channel block on CCt nuclear localization in the adult heart,
paced Langendorff-perfused whole mouse hearts. The primary advantage of this
model system compared to AVMs is that the heart remains intact. Therefore,
cardiomyocytes remain in an environment that is highly similar to in-vivo
conditions, with the exception that sympathetic and parasympathetic innervations
are removed.
To evaluate whether CCt nuclear localization in the Langendorff-perfused
model would mimic CCt nuclear localization in the in-vivo heart, endogenous CCt
nuclear localization was compared between Langendorff-perfused left ventricular
tissue and left ventricular tissue from hearts that were excised and flash frozen.
Langendorff-perfused mouse hearts were paced at 1Hz for 20 minutes in the
presence of 1.8mM calcium. Left ventricular tissue was collected and compared
to left ventricular tissue from hearts that were excised and immediately flashfrozen. Endogenous CCt nuclear localization was measured via western blot with
the CCt antibody, Ab55. Figure 4.2 shows that CCt nuclear localization in the
Langendorff-perfusion model mimics endogenous CCt nuclear localization in the
excised and flash-frozen heart. Approximately 33% of CCt is nuclear localized
under both conditions. This finding suggests that the Langendorff-perfused heart
model is an adequate substitute for the in-vivo heart for measuring CCt nuclear
localization.
Chapter 3 provided evidence that pharmacological L-type calcium channel
block

decreases

endogenous

CCt

nuclear

localization

in

embryonic

cardiomyocytes. Therefore, I chose to test the hypothesis that L-type calcium
channel block also decreases CCt nuclear localization in the adult heart.

65

Treatment with 1µM verapamil visibly blunted contraction of the heart in the
presence of pacing and significantly decreased the percentage of endogenous
CCt in the nuclear fraction to 16%. In Chapter 3, L-type calcium channel block as
well as removal of extracellular calcium was shown to decrease endogenous CCt
nuclear localization in E16 cardiomyocytes. Therefore, the effect on CCt nuclear
localization of removing calcium from the perfusate (0Ca) was tested. Perfusion
with a 0Ca solution visibly stopped contraction, even in the presence of pacing,
and decreased the percentage of CCt nuclear localization to nearly zero. These
findings suggest that calcium entry into the cardiomyocyte is required for CCt
nuclear localization, and mimic the results from embryonic and fetal heart
(Chapter 3).
4.3.2 Pharmacological Inhibition of CCt Phosphorylation Does Not Alter
Nuclear Localization in the Adult Paced Heart
Similar to embryonic cardiomyocytes, calcium regulates CCt nuclear
localization in the adult heart. Therefore, the hypothesis was tested that similar to
over-expressed CCt in embryonic cardiomyocytes (Section 3.5), nuclear
localization of CCt in the adult heart would be regulated by Serine 1928
phosphorylation. Specifically, phosphorylation of Serine1928 would significantly
decrease CCt nuclear localization in the adult heart. Ideally, these experiments
would have initially been done by over-expressing the Serine1928 mutants in the
adult heart and evaluating nuclear localization. However, unlike embryonic
cardiomyocytes, adult cardiomyocytes cannot be transfected. Therefore, the
effects of Serine1928 phosphorylation on endogenous CCt nuclear localization
were tested indirectly by pharmacological manipulation. Agonist stimulation of βand α-adrenergic receptors was used to activate PKA and PKC, respectively,
which should cause Serine 1928 phosphorylation. Stimulation of adrenergic
receptors is known to alter intracellular calcium; therefore these experiments
were performed on a zero calcium background. Adult hearts were perfused for 10
minutes with 0Ca and then stimulated with the β-adrenergic receptor agonist
isoproterenol (ISO) or the α-adrenergic receptor agonist phenylephrine (PE) for
10 minutes. Treatment with either agonist significantly increased nuclear
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localization of CCt to a level equivalent to what was observed in hearts paced in
the presence of calcium. This suggests that activation of PKA and PKC promotes
CCt nuclear localization, possibly via Serine 1928 phosphorylation (Figure 4.3).
To test if active PKA and PKC were responsible for nuclear localization in the
beating heart, CCt nuclear localization was measured in hearts paced at 1Hz in
the presence of calcium with the addition of the PKA inhibitor H-89 or the PKC
inhibitor BIM-I. Treatment with either antagonist did not significantly alter CCt
nuclear localization compared to the paced heart, suggesting that PKA and PKC
may not be involved in regulating CCt nuclear localization in the contracting heart
(Figure 4.4). Calmodulin kinase II (CaMKII) is another kinase present in the heart
that is known to phosphorylate CCt, and furthermore, is regulated by calcium.
Therefore, the effects of the CaMKII inhibitor KN-93 were tested on CCt nuclear
localization in the paced heart. Similar to H-89 and Bim-I, treatment with KN-93
did not significantly alter nuclear localization in the paced heart, suggesting that
CaMKII does not regulate nuclear localization of CCt in the contracting heart
(Figure 4.4).
4.3.3 The Phosphatase Calcineurin May Regulate CCt Nuclear Localization
in the Paced Adult Heart
The previous section suggests that the kinases CaMKII, PKA, and PKC do
not

regulate

CCt

nuclear

localization

in

the

paced

heart.

However,

nucleocytoplasmic transport can also be regulated by dephosphorylation. In
Section 3.5 it was shown that a phosphodeficient mutation of Serine 1928 led to
decreased localization of over-expressed CCt. Therefore it is possible that
dephosphorylation of CCt is a signal for nuclear exclusion in the cardiomyocyte.
Calcineurin is known to be activated by calcium and is capable of binding to and
dephosphorylating CCt [10, 122]. Therefore, the effects of calcineurin inhibition
on CCt nuclear localization were examined. Hearts paced at 1Hz were treated
with the calcineurin inhibitor cyclosporine for 10 minutes. Cyclosporine caused a
dramatic decrease of CCt nuclear localization to 4% (Figure 4.5), which was not
significantly different from 0Ca treatment. To confirm the effect of cyclosporine on
CCt nuclear localization, an alternative pharmacological inhibitor of calcineurin,
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FK-506, was tested. However, treatment with FK-506 did not significantly
decrease CCt nuclear localization compared to paced hearts. Future studies will
need to be performed to clarify whether or not calcineurin regulates CCt nuclear
localization (discussed in Section 4.5)
Pharmacological stimulation of β-adrenergic or α-adrenergic receptors
significantly increased CCt nuclear localization in the absence of calcium (Figure
4.3); it is possible that in this model, adrenergic stimulation regulates CCt nuclear
localization via calcineurin. Therefore, the effects of the calcineurin inhibitors
cyclosporine and FK-506 were tested on β-adrenergic stimulated hearts in the
absence of calcium. Figure 4.6 shows that cyclosporine and FK-506 significantly
decreased nuclear localization compared to isoproterenol (ISO) treated hearts in
the absence of calcium, suggesting that calcineurin may regulate CCt
localization. This raises the question of how adrenergic stimulation is regulating
calcinuerin and in turn regulating CCt nuclear localization. Previous work
provides evidence that both the β-adrenergic and α-adrenergic receptors can
stimulate the MAPK pathway leading to activation of ERK1/2 [123-125]; ERK1/2
in turn can activate calcineurin [126]. To determine if ERK1/2 may be involved in
adrenergic

regulation

of

CCt

nuclear

localization,

the

effect

of

the

pharmacological inhibitor PD-98059 on CCt nuclear localization was tested in
paced hearts and hearts treated with ISO in the absence of calcium. PD-98059 is
an inhibitor of MEK1/2, which is directly upstream of ERK1/2; PD-98059 has
been used extensively in the literature [127-131]. Treatment with PD-98059
decreased nuclear localization of CCt in the paced heart (Figure 4.5) and in the
ISO treated heart (Figure 4.6). This finding suggests that active ERK1/2
promotes accumulation of CCt in the nucleus, perhaps via activation of
calcineurin. To further test this supposition, the ratio of active (phospho-ERK1/2)
to total ERK1/2 was measured via western blot in 0Ca hearts versus ISO treated
hearts. The hypothesis was that isoproterenol treatment would significantly
increase the ratio of active (phosphorylated) ERK1/2. Surprisingly, the ratio of
phospho-ERK1/2 to total ERK1/2 was unchanged with isoproterenol treatment
(Figure 4.7). This finding suggests that in this system, β-adrenergic stimulation
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may not increase nuclear CCt via a pathway that involves phosphorylation of
ERK1/2. However, the opposing results from the PD-98059 studies and the
ERK1/2 western blot render these studies inconclusive. One future study that
needs to be performed is verification that PD-98059 treatment is indeed
significantly decreasing phospho-ERK1/2 under the same conditions where it is
shown to decrease nuclear localization of CCt. This could be done by performing
a western blot similar to Figure 4.7. I intended to perform this experiment;
however, there was not sufficient lysate left over from the CCt nuclear
localization experiment to successfully perform the western blot.
4.3.4 CCt Overexpression Attenuates Serum-Induced Cardiomyocyte
Hypertrophy
Calcineurin is known to regulate the hypertrophic response in the heart
[57, 132]. Pharmacological inhibition of calcineurin attenuates in vitro
cardiomyocyte hypertrophy [133], suggesting that an upregulation of calcineurin
is an important mediator of cardiomyocyte hypertrophy. In the previous section I
provided evidence that pharmacological inhibition of calcineurin decreases
nuclear localization of CCt. Therefore, I wanted to test the hypothesis that CCt
nuclear localization would be increased in in vitro cardiomyocyte hypertrophy.
Dispersed E16 cardiomyocytes were cultured for 24 hours in media containing
10% fetal bovine serum (serum) or media lacking serum (serum free). Serum
induced E16 cardiomyocyte hypertrophy. This was evident by serum increasing
cardiomyocyte cell area by 25%(+/-5%) and increasing ANF promoter activity. To
test the effect of serum-induced hypertrophy on CCt localization, eGFP18212171 and eGFP1906-2171 were over-expressed in E16 cardiomyocytes treated
with our without serum. Figure 4.8 shows that serum did not significantly alter
nuclear localization of eGFP1821-2171 or eGFP1906-2171. However, overexpression of CCt did significantly attenuate serum-induced hypertrophy. As
shown in Table 1, eGFP1821-2171 and eGFP1906-2171 significantly decreased
cell size compared to eGFP transfected cells treated with serum. Representative
images are shown in Figure 4.9. Dr. Schroder showed that over-expression of
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CCt significantly decrease ANF promoter activity, providing a plausible
mechanism by which CCt attenuates hypertrophy [29].
Serum-induced hypertrophy did not significantly alter nuclear localization
of over-expressed CCt. However, this may have been due to the confound of
over-expressed CCt attenuating the hypertrophic response. Dr. Schroder
performed an experiment comparing endogenous CCt nuclear localization in E16
cardiomyocytes treated for 24 hours. Dr. Schroder’s results indicated that seruminduced hypertrophy significantly increased endogenous CCt nuclear localization
[29].
4.3.5 Pathological Hypertrophy Induced by Isoproterenol does not Alter CCt
Nuclear Localization
Serum-induced cardiomyocyte hypertrophy significantly increases nuclear
localization of endogenous CCt [29]. This finding suggests that CCt nuclear
localization may also be altered in whole-heart pathological hypertrophy.
Therefore, I wanted to test the hypothesis that CCt nuclear localization is
increased in a whole-animal model of pathological cardiac hypertrophy.
Isoproterenol-induced cardiac hypertrophy is a well described and well studied
model of pathological cardiac hypertrophy [134-136]. Additionally, our lab has
previously published work using a model of osmotic pump delivered isoproterenol
in mice [112]. Therefore, a mouse model of isoproterenol-induced pathological
hypertrophy was utilized to study the effects of pathological hypertrophy on CCt
nuclear localization. Osmotic pump implantation and echocardiography were
performed by Carmen Kiper. Mice treated for 2 weeks with isoproterenol
exhibited a significant increase in heart weigh, heart weight to body weight ration,
and left ventricular wall thickness, indicating the presence of cardiac hypertrophy.
To confirm that hypertrophy was also present at a molecular level, ANF
expression levels were measured. I predicted that expression would be
increased since ANF is a marker of cardiac hypertrophy. However, 2 week
treatment with isoproterenol did not significantly alter ANF expression compared
to control (Figure 4.10); this may be explained by the fact that apex tissue was
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used for measuring ANF expression, as all left ventricular tissue was used for
evaluating CCt localization. Endogenous CCt nuclear localization was measured
using left ventricular free wall from isoproterenol treated animals. CCt nuclear
localization was not significantly different between isoproterenol treated animals
and control (Figure 4.11). In tandem, CaV1.2 expression was also unchanged in
isoproterenol treated mice (Figure 4.10).
4.3.6 Physiological Hypertrophy Induced by Pregnancy May Alter CCt
Nuclear Localization
In addition to pathological hypertrophy, the heart can also undergo
physiological hypertrophy in response to chronic exercise or pregnancy. In
pregnant rats, expression of the L-type calcium channel subunit increases
throughout the duration of pregnancy and then decreases during parturition [137138]. In Chapter 3, I provided evidence that CCt acts as a repressor of CaV1.2
transcription. Therefore, I tested the hypothesis that CCt nuclear localization is
decreased in a murine model of pregnancy. Left ventricular tissue was isolated
from mice at day 18 of pregnancy. Parturition occurs at day 20 of pregnancy.
Endogenous CCt nuclear localization was measured via western blot. Mean CCt
nuclear localization was not significantly altered in pregnant mice compared to
non-pregnant female mice (Figure 4.12). However, there was a large variation in
CCt nuclear localization between individual pregnant mice, as evident by the
large standard deviation. Physiological hypertrophy in the heart is induced by an
increase in work load on the heart. It is possible that different litter sizes produce
different amounts of work load on the heart, thereby inducing differing degrees of
physiological hypertrophy. Therefore, the hypothesis was tested that litter size
directly correlates with CCt nuclear localization in the pregnant mouse heart.
Litter size was plotted versus CCt nuclear localization. Figure 4.12B indicates
that there is no correlation between litter size and CCt nuclear localization. Upon
further analysis of the individual data it was discovered that all of the pregnancy
nuclear CCt values fell outside of the range of the mean nuclear CCt (30%+/4%). Nine of the pregnant mice showed decreased CCt nuclear localization
compared to the mean while only five showed increased CCt nuclear localization.
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It is possible that the five mice with increased CCt nuclear localization were
undergoing premature parturition, where CaV1.2 expression is decreased. A
future experiment to test this supposition would be to measure CaV1.2
expression in the pregnant mice. I would predict that the nine mice with
decreased CCt nuclear localization would have increased CaV1.2 expression,
consistent with pregnancy. In turn, the five mice with increased CCt nuclear
localization would have decreased CaV1.2 expression, consistent with parturition.
4.4 Discussion
The primary finding of this chapter is that L-type calcium channel block
and perfusion with a calcium-free buffer significantly decrease endogenous CCt
nuclear localization in the adult modified Langendorff-perfused heart (Figure
4.2). This is in tandem with the finding in Chapter 3 that L-type calcium channel
block and treatment with 0Ca+0.3mM EGTA decrease endogenous CCt nuclear
localization in embryonic cardiomyocytes (Figure 3.6). However, there is a
significant difference in the time-course that was utilized in the two models
studied. In the adult heart, CCt nuclear localization was measured on the order of
minutes, while changes in embryonic and fetal cardiomyocyte CCt nuclear
localization were observed on the order of days. Therefore, it would be
interesting to test both a short and long time course in both model systems. An
attempt was made to test changes in nuclear localization of over-expressed
eGFP1821-2171 on the order of minutes using FRAP (Section 3.4). However,
these experiments were not feasible due to the fact that eGFP and eGFP18212171 localized to the photobleached nucleus of E16 cardiomyocytes over the
same time course. If a CCt antibody suitable for immunocytochemistry was
available, then it would be possible to study the regulation of endogenous CCt
nuclear localization in embryonic cardiomyocytes over a short time course. It
would also be interesting to study the effects of long-term calcium channel block
on

CCt

nuclear

localization

in

the

adult

heart.

Unfortunately,

adult

cardiomyocytes cannot be cultured for an extended period. Our lab previously
studied a mouse model where verapamil was delivered via an osmotic pump for
48 hours [112]. An interesting future study would be to examine nuclear
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localization of CCt in these mouse hearts, especially since these hearts exhibited
an increase in CaV1.2 protein and expression. I would hypothesize that 48 hour
verapamil treatment would significantly decrease CCt nuclear localization
compared to control animals.
In this chapter, the role of PKA and PKC in regulating CCt nuclear
localization was measured indirectly by 10 minute application of adrenergic
receptor agonists. Pharmacological stimulation of β-adrenergic and α-adrenergic
receptors significantly increased CCt nuclear localization in the absence of
external calcium and pacing. This finding was opposite of the observed decrease
in nuclear localization of over-expressed CCt with a phosphomimetic mutation of
S1928 (Figure 3.7). It is possible that in the over-expression model, the excess
amount of CCt that is inherently produced is transported in and out of the nucleus
by mechanisms other than those that regulate physiological nuclear localization
of endogenous CCt. To determine if PKA or PKC phosphorylation regulated
endogenous CCt nuclear localization in the paced heart, pharmacological
inhibitors were utilized, with the result that inhibition of either kinase did not alter
CCt nuclear localization. This finding suggested that β-adrenergic and αadrenergic receptors regulate CCt nuclear localization via a mechanism that is
independent of PKA or PKC phosphorylation. I hypothesized that the βadrenergic and α-adrenergic receptors regulate CCt nuclear localization via
activation of ERK1/2. However, experiments to test this hypothesis were
inconclusive. Pharmacological inhibition of β-adrenergic stimulated hearts with
PD-98059 significantly decreased CCt nuclear localization, suggesting that
ERK1/2 regulates CCt nuclear localization. In contrast, immunoblot with
antibodies specific to phosphorylated ERK1/2 indicated that β-adrenergic
stimulated did not induce a significant change in the amount of phosphorylated
ERK1/2. A follow-up experiment that needs to be performed is to test whether or
not PD-98059, at the concentration used, does indeed decrease the amount of
phosphorylated (active) ERK1/2. If PD-98059 does not significantly decrease the
amount of phosphorylated ERK1/2, then the conclusion can be made that PD-
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98059 alters CCt nuclear localization via a mechanism that does not involve
ERK1/2.
Another potential regulator of CCt localization studied in this chapter was
the phosphatase calcineurin. Unfortunately, these studies did not provide
conclusive evidence as to whether or not calcineurin regulates CCt nuclear
localization. Treatment with the calcineurin inhibitors cyclosporine and FK-506
significantly decreased CCt nuclear localization in isoproterenol treated hearts on
a calcium free background (Figure 4.5). However, only cyclosporine decreased
nuclear localization in paced hearts (Figure 4.4). Upon review of the literature, it
was discovered that FK-506 can increase SR calcium release at rest and during
contraction in rat ventricular myocytes [139]. An increase in cytosolic calcium
alone should increase CCt nuclear localization since L-type calcium channel
block and 0Ca decrease CCt nuclear localization. However, if calcineurin was the
only pathway by which calcium regulates CCt nuclear localization, than the FK506 co-effect of calcineurin blockade should have decreased nuclear localization
despite an increase in calcium. This raises the possibility that calcium regulates
CCt nuclear localization via multiple pathways, including calcineurin. It is also
possible that calcineurin is not directly involved in CCt nuclear localization and
that the pharmacological effects observed were due to unknown non-specific
effects on the heart.
In this chapter I tested the hypothesis that hypertrophy increases nuclear
localization of CCt. Endogenous CCt nuclear localization was increased in a
model of serum-induced hypertrophy in both adult cardiomyocytes and
embryonic

cardiomyocytes.

Over-expression

of

CCt

in

embryonic

cardiomyocytes attenuated the serum-induced hypertrophic response within 24
hours. A possible mechanism for over-expressed CCt attenuation of hypertrophy
is that over-expressed CCt transcriptionally regulates genes involved in the
hypertrophic response. Evidence to support this theory is provided by Figure
4.10, which shows that CCt suppresses ANF promoter activity. The theory that
CCt transcriptionally regulates genes involved in the hypertrophic response
warrants further testing, as it could potentially have important clinical implications
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for treating pathological cardiac hypertrophy. It would be interesting to see if CCt
was capable of regulating the promoters of other genes involved in the
hypertrophic response, such as the embryonic β-myosin heavy chain or skeletal
α-actinin [69]. It would also be interesting to perform a microarray study to
compare gene expression profiles of cardiomyocytes treated with serum versus
CCt over-expressing cardiomyocytes treated with serum. This may lead to the
identification of novel genes regulated by CCt. Another possible mechanism for
over-expressed CCt attenuation of hypertrophy is that over-expressed CCt
attenuates hypertrophy via its ability to alter sarcoplasmic reticulum calcium load
(Figure 3.4). The calcium imaging experiments in Figure 3.4 were all performed
in the presence of serum. This warrants future exploration as to the effects of
CCt over-expression on calcium handling under serum versus serum free
conditions to determine if they are the same.
Serum-induced hypertrophy was shown to significantly increase nuclear
localization of CCt in cultured cardiomyocytes. This led to the question of
whether CCt nuclear localization would also be altered in an animal model of
pathological cardiac hypertrophy. A murine model of isoproterenol-induced
cardiac hypertrophy revealed that endogenous CCt nuclear localization was
unchanged. While echocardiography revealed structural changes in the heart
consistent with hypertrophy, ANF expression from apex tissue was unchanged.
Ideally, these experiments would need to be repeated and ANF measured from
left ventricular tissue to determine if there was indeed an induction of
hypertrophic gene expression in this animal model. However, upon reflection,
isoproterenol-induced cardiac hypertrophy may not be the best model for
studying the effects of pathological cardiac hypertrophy on nuclear localization of
CCt. In Figure 4.3, I provided evidence that acute adrenergic stimulation with
isoproterenol increases nuclear localization of CCt in the absence of calcium. It is
possible that long-term adrenergic stimulation is adding an extra confound and
ultimately masking any hypertrophic-specific effects on CCt nuclear localization.
Therefore, instead of pursuing the isoproterenol-induced cardiac hypertrophy
model I would like to look at CCt nuclear localization in a non-pharmacologically
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induced model of cardiac hypertrophy, such as the aortic-banding model or
spontaneous hypertensive rat model [140]. I would also like to measure CCt
nuclear localization in cardiac tissue from human subjects exhibiting cardiac
hypertrophy to establish the clinical relevancy of CCt.
In this chapter, CCt nuclear localization was also studied in a wholeanimal

model

of

physiological

cardiac

hypertrophy.

Pregnancy-induced

hypertrophy was used as a model because previous studies have shown that
these hearts exhibit an increase in CaV1.2 expression, which would
hypothetically correlate with a decrease in CCt nuclear localization. Mean values
collected from fourteen pregnant mice showed no significant difference in CCt
nuclear localization compared with non-pregnant controls. However, there may
have been the complication of premature parturition affecting the data. A future
experiment would be to look at pregnant animals from an earlier time-point, such
as day 16 of pregnancy, to decrease the possibility of premature parturition.
Additionally, CaV1.2 message should be measured along with CCt nuclear
localization in order to determine if there is a direct correlation between the two in
this animal model.
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Figure 4.2 L-type calcium channel block and 0Ca decrease endogenous
CCt nuclear localization in the adult left ventricle. A) Adult mouse hearts
were langendorff-perfused and paced at 1Hz for 20 minutes (n=4) in order to
mimic CCt nuclear localization observed in the immediately excised heart.
Treatment with verapamil (n=3) or zero calcium (n=3) in the presence of pacing
significantly decreased nuclear localization (*p<0.03 vs paced; t-test). B)
Representative cytosolic and nuclear western blots from each condition probed
with Ab55. GAPDH is primarily in the cytosolic fraction, while PolII is primarily in
the nuclear fraction. “Cyt” indicates cytosolic fraction and “Nuc” indicates nuclear
fraction. The CCt band, which is ~37kDa is indicated by an arrow.
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Figure 4.3 Adrenergic stimulation regulates CCt nuclear localization
independent of calcium. Hearts perfused with 0Ca solution for 10 minutes in
the absence of pacing showed a significant decrease in nuclear localization
compared to hearts paced at 1Hz in the presence of 1.8mM Ca (*p=0.01; t-test).
Treatment with 1µM isoproterenol (ISO) or 20µM phenylephrine (PE) in the
presence of 0Ca and no pacing restored CCt nuclear localization to levels not
significantly different from control. (Note: these treatments are independent of
Figure 4.2)
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Figure 4.4 Inhibition of CaMKII, PKA, or PKC does not affect CCt nuclear
localization in the paced adult heart. Adult mouse hearts were langendorffperfused and paced at 1Hz for 10 minutes in the absence or presence of
pharmacological agent. Treatment with the CaMKII inhibitor KN-93, the PKA
inhibitor H-89, or the PKC inhibitor BIM-I did not significantly later CCt nuclear
localization. (Note: 1Hz Paced data is from Figure 4.3)
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Figure 4.5 Calcineurin and ERK1/2 inhibition decrease CCt nuclear
localization in the paced adult heart. Hearts were paced at 1Hz for 10 minutes
and treated with the calcineurin inhibitors cyclosporine and FK-506 or the
ERK1/2 inhibitor PD98059 for 10 minutes. Cyclosporine and PD98059 decrease
CCt nuclear localization while FK-506 had no effect. (*p<0.05; t-test). (Note: 1Hz
Paced data is from Figure 4.3)
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Figure 4.6 Calcineurin and ERK1/2 inhibition significantly reduce the effect
of isoproterenol on CCt nuclear localization. Hearts were perfused with a 0Ca
solution for 10 minutes then treated with isoproterenol with or without the addition
of a calcineurin inhibitor (cyclosporine or FK-506) or an ERK1/2 inhibitor
(PD98059). Treatment with any of the inhibitors significantly decreased CCt
nuclear localization compared to isoproterenol treatment alone. (*p<0.05; t-test).
(Note: 0Ca, Not Paced and 1µM ISO are from Figure 4.3)
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Figure 4.7 Isoproterenol treatment does not Increase the ratio of phosphoERK1/2. Hearts were perfused in a 0Ca solution for 10 minutes then treated with
1µM isoproterenol for 10 minutes. Western blots were probed with phosphoERK1/2 and ERK1/2. There was no significant difference in the relative phosphoERK1/2 integrated density in 0Ca solution versus 0Ca+ISO (n=3 for each
condition; p>0.1).
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Figure 4.8 Serum treatment does not significantly alter nuclear localization
of over-expressed CCt. The ratio of nuclear to cytosolic eGFP intensity was
measured in E16 cardiomyocyte cultured in serum (FBS) or cultured in serum
free media (SF) for 24 hours. eGFP transfected controls exhibited a significant
increase in nuclear/cytosolic intensity that was not mimicked by eGFP1821-2171
(1821) or eGFP1906-2171 (1906) over-expression.
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Figure 4.9 Representative confocal images. E16 cardiomyocytes were
transfected with eGFP, eGFP1821-2171, or eGFP1906-2171 and cultured in the
presence or absence of serum for 24 hours. α-actinin is a cardiomyocyte-specific
marker. (white scale bar = 40µM).
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Figure 4.10 Expression of CaV1.2 and ANF are not changed in
isoproterenol-induced induced pathological cardiac hypertrophy. Real-time
RT-PCR was performed on cDNA collected from the apex of 2-week
isoproterenol treated animals or saline controls. Data is represented as a fold
change in expression from control. There was no significant statistical change in
expression of either gene.
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Figure 4.11 Isoproterenol-induced induced pathological cardiac
hypertrophy does not significantly alter CCt nuclear localization. A)
Isoproterenol was delivered for 2 weeks via osmotic pump at a rate of
3mg/kg/day (performed by Carmen Kiper). Saline was used as a control. The
results from western blots performed by myself indicate that there was no
statistically significant difference in left ventricular CCt nuclear localization
between the two conditions.
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Figure 4.12 Pregnancy-induced physiological cardiac hypertrophy does not
conclusively alter CCt Nuclear Localization. A) Left ventricular tissue collected
from non-pregnant female mice (excised control heart) or female mice pregnant
for 18 days (Day 18 Pregnant Heart) showed no significant difference in mean
CCt nuclear localization. B) A plot of litter size versus CCt nuclear localization
indicates no correlation between the two. However, CCt nuclear localization in all
pregnant mice fall outside range of the mean (black line, 30%) +/- standard
deviation (dotted line, 4%) nuclear localization in the non-pregnant female mice.
See Section 4.3.6 for further explanation.
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Chapter 5: Dissertation Summary
The work presented in this dissertation project provides evidence in
support of my global hypothesis; CCt localizes to the nucleus in embryonic and
adult cardiomyocytes via a calcium-mediated mechanism and regulates
transcription.
Chapter 2 established an in-vitro model for studying the effects of
pharmacological L-type calcium channel block on cardiac development at E10.
Utilizing this model, evidence was provided that cardiogenesis is not perturbed
by a general perturbation of intracellular calcium (i.e. removal of extracellular
calcium or pharmacological inhibition of sarcoplasmic reticulum calcium release).
Instead, cardiogenesis appears to be perturbed by a mechanism that directly
involves the L-type calcium channel; pharmacological L-type calcium channel
block perturbed embryonic cardiogenesis. An additional observation made was
that L-type calcium channel block induced a resistance response in a subset of
embryonic ventricular cardiomyocytes. This resistance response consisted of all
ventricular cardiomyocytes exhibiting no change in sarcoplasmic reticulum
calcium load and a subset of ventricular cardiomyocytes exhibiting spontaneous
calcium transients and no change in trans-sarcolemmal diastolic calcium entry in
response to acute L-type calcium channel block challenge. The mechanism for
this L-type calcium channel block resistance response is unknown. However, this
compensatory resistance response does enforce the idea that the L-type calcium
channel is important in heart development; the developing heart attempts to
compensate for pharmacological L-type calcium channel block.
Interestingly, pharmacological L-type calcium channel block does not
visibly perturb the embryonic heart at E16. This is most likely due to the fact that
at E16, the heart has completed cardiogenesis and is instead undergoing growth.
However, L-type calcium channel block does induce the resistance response
observed in E10 cardiomyocytes. The presence of this resistance response
again emphasizes the importance of the L-type calcium channel heart.
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Chapter 3 examined whether or not CCt is able to localize to the nucleus
in embryonic cardiomyocytes. Over-expression of two pieces of the CaV1.2
carboxyl-terminus,

one

containing

(eGFP1821-2171)

and

one

lacking

(eGFP1906-2171) a purported nuclear retention domain observed in neurons,
revealed that both localized to the nucleus of embryonic cardiomyocytes. In fact,
eGFP1906-2171 exhibited greater nuclear localization than eGFP1821-2171;
according to findings in the neuronal model eGFP1906-2171 should not have
localized to the nucleus. A possible explanation for this contradictory result in
cardiomyocytes is that nuclear localization of CCt is regulated by different
pathways in neurons and cardiomyocytes. This raised the question of whether or
not calcium regulates CCt nuclear localization in cardiomyocytes similar to
neurons. Treatment of embryonic cardiomyocytes with pharmacological L-type
calcium channel block significantly decreased over-expressed eGFP1821-2171
localization and trended towards decreasing over-expressed eGFP1906-2171.
This result was the exact opposite of that observed in neurons; in neurons,
pharmacological calcium channel block increased CCt nuclear localization. This
finding suggests that CCt nuclear localization is, in fact, regulated differently in
cardiomyocytes versus neurons. To further confirm this postulate, endogenous
CCt nuclear localization in embryonic cardiomyocytes was also examined via
immunoblot. These results mimicked what was observed with the overexpression system.
Chapter 3 also examine whether or not CCt plays a function role in the
nucleus. Over-expression of eGFP1821-2171, which as mentioned above is
localized to the nucleus, correlated with a decrease in CaV1.2 expression.
Conversely, treatment with L-type calcium channel block, which decreases
nuclear localization of over-expressed and endogenous CCt, correlated with an
increase in CaV1.2 expression. These findings suggested that CCt may be
regulating CaV1.2 transcription. A follow-up study examining the ability of overexpressed CCt to regulate the CaV1.2 reporter revealed that CCt represses the
CaV1.2 promoter. This experiment was performed by Dr. Schroder after I
attempted the experiment numerous times. Dr. Schroder provided further
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evidence that CCt regulates the CaV1.2 in published work showing that CCt binds
to the CaV1.2 promoter [29].
To further determine the mechanism regulating CCt nuclear localization, I
tested the hypothesis that calcium regulates CCt nuclear localization by
mediating CCt phosphorylation or dephosphorylation. In Chapter 3, overexpression of Serine1928 mutated CCt constructs in E16 cardiomyocytes
suggested that phosphorylation of Serine1928 decreased nuclear localization of
CCt. This would suggest that activation of PKA and PKC, two kinases that
phosphorylate Serine1928, would increase nuclear localization. This was indeed
the finding in Chapter 4; adult hearts treated with α- and β-adrenergic receptor
agonists showed increased CCt nuclear localization in the absence of calcium.
However, in the paced adult heart, inhibition of PKA and PKC did not conversely
decrease CCt nuclear localization. This suggests that while PKA and PKC may
be able to regulate CCt nuclear localization, it is probable that these two kinases
are not the primary physiological regulators of CCt nuclear localization in the
heart where calcium is present.
An alternative mediator of CCt nuclear localization explored was the
protein phosphatase calcineurin. In

Chapter

4,

pharmacological

block

of

calcineurin with cyclosporine decreased CCt nuclear localization in both paced
and

adrenergic

receptor

agonist

treated

hearts.

Furthermore,

indirect

pharmacological block of the known calcineurin activator ERK1/2 decreased CCt
nuclear localization in paced and adrenergic receptor agonist treated hearts.
Collectively, these findings suggest that both calcium and adrenergic receptors
regulate CCt nuclear localization via a pathway involving ERK1/2 and calcineurin.
However, a western blot of active (phosphorylated) ERK1/2 versus total ERK1/2
did not support this posit. While the findings in Chapter 4 support that calcineurin
regulates CCt nuclear localization, they are not conclusive as to whether or not
ERK1/2 is involved. The components of the pathway linking the L-type calcium
channel and adrenergic receptors to calcineurin and CCt nuclear localization still
need to be determined.
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Another question studied in this dissertation was the physiological
relevance of CCt nuclear localization. In Chapters 2 and 3, I showed that
pharmacological L-type calcium channel block, specifically, perturbs embryonic
cardiogenesis and that pharmacological L-type calcium channel decreases
nuclear localization of the transcription factor CCt in embryonic cardiomyocytes.
This correlation suggests that L-type calcium channel block perturbs embryonic
cardiogenesis by decreasing CCt nuclear localization. However, what is lacking
is data showing that CCt in and of itself is capable of regulating embryonic
cardiogenesis.
Chapter 4 provided evidence that CCt nuclear localization plays a role in
the

serum-induced

hypertrophic

response

in

embryonic

and

adult

cardiomyocytes. Work published by Dr. Schroder indicates that endogenous CCt
nuclear localization is increased in the serum-induced hypertrophic model [29].
When I over-expressed CCt in the serum-induced hypertrophic model,
surprisingly, the hypertrophic response was attenuated; cell size and ANF
expression decreased. This model suggests that over-expression of CCt may
prove to be a future therapeutic tool for cardiac hypertrophy. However, the
mechanism by which over-expressed CCt attenuates hypertrophy first needs to
be determined.
To further establish a role for CCt in cardiac hypertrophy, CCt nuclear
localization was measured in a model of adult, isoproterenol-induced pathological
hypertrophy

and

adult,

pregnancy-induced

physiological

hypertrophy.

Unfortunately, these models had confounding problems that made their results
inconclusive. In the model of pathological hypertrophy, two week treatment with
isoproterenol significantly increased heart weigh, heart weight to body weight
ration, and left ventricular wall thickness as indicated by echocardiography
performed by Carmen Kiper. These are all hallmarks of hypertrophy. However,
measurement of expression of the hypertrophic gene ANF in the apex of these
hearts showed that there was no significant change in expression with
isoproterenol treatment. These conflicting results suggest that this isoproterenol
treatment model was not a clear model of pathological hypertrophy. Therefore
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the lack of an effect on CCt nuclear localization that was observed is not
conclusive. Future experiments will need to be performed in a pathological
hypertrophy model that exhibits both structural and hypertrophic gene expression
changes in order to determine if CCt nuclear localization is altered in
hypertrophy. The confounding problem in the pregnancy-induced physiological
hypertrophy model was the possibility that premature parturition was affecting the
data. Therefore, these experiments will need to be repeated in an alternative
model, such as an earlier time point of pregnancy when the likelihood of
premature parturition is very low. In summary, while there is evidence to support
a role for CCt in a model of cellular hypertrophy, it is unclear whether CCt plays a
role in an animal model of whole-heart hypertrophy. Future studies will need to
be performed to clarify this issue.
Based on the results from this dissertation there are two models that I
propose for the role of CCt in the embryonic and adult heart. In the first model,
CCt acts as an auto-regulation of CaV1.2 expression in cardiomyocytes (Figure
5.1). Calcium enters via CaV1.2 and promotes nuclear localization of CCt via
calcineurin. In the nucleus, CCt acts as a suppressor of the CaV1.2. Therefore,
more CaV1.2 channel is not made. However, if calcium entry via CaV1.2 is
blocked, CCt is not localized to the nucleus. There is no suppression of the
CaV1.2 promoter; therefore more CaV1.2 channel is made. The second model I
propose is that CCt regulates genes that are important for both embryonic
development and the induction of pathological cardiac hypertrophy (Figure 5.2).
In the embryonic heart, developmental cues, which may include calcium entry via
CaV1.2, promote nuclear localization of CCt. Nuclear CCt regulates the
transcription of genes that are essential for embryonic development. In the adult
heart, stimuli of pathological hypertrophy, which may include adrenergic receptor
stimulation and CaV1.2 calcium entry, promote nuclear localization of CCt.
Nuclear CCt regulates the transcription of genes that are involved in the
development of pathological cardiac hypertrophy. Future studies will need to be
performed to establish the validity of these two proposed models. These studies
should include investigations as to the exact mechanism(s) by which CCt nuclear
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localization is regulated and also the specific physiological role(s) that CCt plays
in the heart. A mouse model that would be extremely useful for these future
studies would be an inducible, transgenic mouse that exclusively expressed
CaV1.2 lacking CCt in the heart. In context of my first proposed model (figure
5.1), I hypothesize that this mouse model would display increased expression of
CaV1.2 compared to wild-type mice. In context of my second model (Figure 5.2), I
hypothesize that this mouse model, when induced during development, would
display perturbed cardiogenesis. In the adult heart, I hypothesize that induction of
a CCt deletion would diminish the ability of the adult heart to hypertrophy in
response to pathological hypertrophic stimuli.
There are two important questions that are raised by this dissertation work
that need to be addressed in future studies. First, my dissertation finding
suggests that calcium entering through the L-type calcium channel regulates CCt
nuclear localization (Figures 5.1 and 5.2). This raises the question of how this
calcium, which enters cardiomyocytes on a beat-to-beat basis, can also signal to
CCt. This is a question that has been raised by the field, but has yet to be
answered [10, 141-142] One hypothesis is that CaV1.2 is located in two separate
domains in cardiomyocytes [10]. In one domain, CaV1.2 is in complex with RYR
and sarcoplasmic reticulum where it functions solely in excitation-contraction
coupling. In the second domain CaV1.2 is not in complex with RYR and is solely
involved in signaling, not in excitation-contraction coupling. If there was a CCt
antibody available that was suitable for immunocytochemistry, then embryonic
and adult cardiomyocytes could be probed for CCt along with CaV1.2 and RYR to
see if CCt associates with CaV1.2 in complex with RYR.
The second question this dissertation work raises is how CCt can both be
in a complex with CaV1.2, influencing channel function, and localized to the
nucleus regulating transcription. One hypothesis is that not all cleaved CCt is
associated with channel, leaving a portion of CCt available to be shuttled
between the nucleus and cytosol. A second hypothesis is that CCt is transcribed
separately from full-length CaV1.2, thereby allowing for production of independent
CCt protein that is able to act as a transcription factor in the cardiomyocyte. To
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begin testing the first hypothesis, co-immunoprecipitation experiments could be
performed to see if there is CaV1.2 present that is not associated with CCt. For
testing of the second hypothesis, a mouse CaV1.2 knockout model would be
ideal [90]. Using this model, Real-time RT-PCR could be performed to determine
if a CCt transcript was present when no CaV1.2 is being made.
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